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ABSTRACT 
 
Increasingly intensive antineoplastic regimes have been effective in the treatment for 
haematological malignancies, but as effective as it is in limiting neoplasm of the 
malignant cells, bystander damage occurs equally to cells of the immune system and 
epithelial cells of the mucosa.  Infectious complications following chemotherapy reflect 
this situation. 
 
The relationship between leukocytopaenia and infection risk, in the form of 
bacteraemia and fungaemia was first suggested by Bodey and colleagues and since 
then, many studies have followed establishing the breadth of pathogens in relation to 
neutropaenia.  However, lymphocytes are also concurrently, markedly reduced 
suggesting that viraemia should also be considered in the repertoire of infectious 
complications with these iatrogenic neutropaenic patients.  Reactivation of latent DNA 
viruses, for example, members of the herpesviridae family, and respiratory viruses have 
been reported in severely immunosuppressed patients after haematopoiesis stem cell 
transplantation (HSCT) but less so in patients that have been administered 
comparatively less aggressive chemotherapeutic treatment used against hematological 
malignancies.  Since fever in these patients is sometimes the only indication of 
infection due to their immunosuppressed state, we not only determined the prevalence 
of viral infections in the iatrogenic neutropaenic adult patient we also related our 
findings to fever manifestation.  Indeed, an association between virus detection and 
fever was observed, suggesting viral contribution to 30% of neutropaenic febrile 
episodes in our study cohort.  
 
In addition to immune cell depletion, disruption of the gastrointestinal mucosa is 
another major side-effect since it can lead to microbial translocation from the large 
reservoir of bacterial microflora we harbour in our bowels.  Elevated plasma 
endotoxins and sCD14 was observed in the bacteraemic episodes as well as in the 
episodes with fever of unknown origin (FUO).   So, together with the 33% of the febrile 
episodes attributed to clinically documented bacteraemia and 30% attributed to viruses, 
we propose that aside from drug and tumour fever, a part of the remaining 37% of 
febrile neutropaenic episodes could be attributed to microbial translocation of bacterial 
products from the gut. 
 
Acellular components of the immune system, such as the acute phase protein, mannose-
binding lectin (MBL) have been suggested to be important in a similar cohort and that 
the use of replacement MBL therapy could be administered to reduce duration of 
febrile neutropaenic episodes.  We however, did not observe any associations between 
MBL and infection type or frequency and add to the reports casting doubts on the 
benefit of recombinant therapy in the iatrogenic neutropaenic adult. 
 
In conclusion, we have added to the panorama of infectious agents and bacterial 
products implicated during febrile neutropaenic episodes in the adult iatrogenic patient 
and have further discouraged suggestions for MBL replacement therapy. 
 4 
   5 
LIST OF PUBLICATIONS AND MANUSCRIPTS 
 
I. MICHELLE WONG, Lars Öhrmalm, Carl Aust, Martin Hibberd, Kristina 
Broliden and Thomas Tolfvenstam. 
Mannose-binding lectin polymorphisms do not influence the frequency of 
infections in adults with neutropenia. 
PLoS ONE. 2012; 7(2):e30819. Epub 2012 Feb 17. 
 
 
II. Lars Öhrmalm, MICHELLE WONG, Carl Aust, Per Ljungman, Oscar 
Norbeck, Kristina Broliden and Thomas Tolfvenstam. 
Virus association to fever in adult neutropenic patients with 
hematological disorders: a cross sectional study. 
Manuscript submitted. 
 
 
III. Lars Öhrmalm, MICHELLE WONG, Maria Rotzén-Östlund, Oscar Norbeck, 
Kristina Broliden and Thomas Tolfvenstam. 
Flocked nasal swab versus Nasopharyngeal aspirate for detection of 
respiratory tract viruses in immunocompromised adults : a matched 
comparative study. 
BMC Infect Dis. 2010 Nov 26; 10:340. 
 
 
IV. MICHELLE WONG, Babilonia Barqosho, Lars Öhrmalm, Thomas 
Tolfvenstam and Piotr Nowak. 
Microbial translocation contribute to febrile episodes in adults with 
chemotherapy –induced neutropaenia. 
Manuscript submitted. 
 
 
 6 
CONTENTS 
1  Preface ........................................................................................................................ 9 
2  Introduction .............................................................................................................. 10 
2.1  The immunocompromised host ..................................................................... 10 
2.1.1  Haematological malignancies ............................................................ 10 
2.1.2  General treatment strategies ............................................................... 11 
2.1.3  Febrile neutropaenia in the iatrogenic immunosuppressed patient .. 12 
2.2  Infectious complications ................................................................................ 12 
2.2.1  Bacteraemia ........................................................................................ 14 
2.2.2  Invasive fungal infections (IFI) ......................................................... 14 
2.2.3  Viraemia ............................................................................................. 15 
2.2.4  Polymicrobial infections .................................................................... 22 
2.2.5  Microbial translocation ...................................................................... 22 
2.3  Viral detection methods in immunosuppressed patients ............................... 24 
2.3.1  Virus culture and direct visualisation ................................................ 24 
2.3.2  Viral antigaenic detection .................................................................. 25 
2.3.3  Serology .............................................................................................. 25 
2.3.4  Molecular detection ............................................................................ 26 
2.4  Immune alterations in the immunosuppressed host ...................................... 27 
2.4.1  Adaptive immune system................................................................... 28 
2.4.2  Innate immune system ....................................................................... 29 
3  Aims of the thesis ..................................................................................................... 32 
4  Patients, Materials and Methods .............................................................................. 33 
4.1  Patients and inclusion criteria ........................................................................ 33 
4.2  Materials ......................................................................................................... 33 
4.3  Methods .......................................................................................................... 34 
4.3.1  Flocked nasal swab and nasal pharyngeal aspirate collection .......... 34 
4.3.2  Quantitative PCR (qPCR) for detection of viruses ........................... 35 
4.3.3  Fluorescence-activated cell sorting ................................................... 37 
4.3.4  ELISA ................................................................................................. 37 
4.3.5  Single Nucleotide Polymorphism (SNP) identification .................... 37 
4.3.6  Chromogenic Limulus Amoebocyte Lysate (cLAL) assay .............. 37 
4.3.7  Statistical analysis .............................................................................. 38 
5  Results and Discussion ............................................................................................. 40 
5.1  Virus detection and characterisation .............................................................. 41 
5.2  Microbial Translocation Contributes to episodes with Fever of Unknown 
Origin ........................................................................................................................ 47 
5.3  MBL2 polymorphisms and infection susceptibility ....................................... 51 
6  Conclusion and Future Perspectives ........................................................................ 57 
7  Popular Science Summary ....................................................................................... 60 
8  Acknowledgements .................................................................................................. 62 
9  References ................................................................................................................ 64 
 
   7 
LIST OF ABBREVIATIONS 
 
AdV Adenovirus 
ALL Acute lymphoid leukaemia 
AML Acute myeloid leukaemia 
ANC Absolute neutrophil counts 
BKV BK polyomavirus 
CAR Coxsackie B and adenovirus receptor 
CMV Cytomegalovirus 
CPE Cytopathic effects 
CRP C-reactive protein 
CRP C-reactive protein 
CRV Community acquired Respiratory viruses 
CT Cycle threshold 
DC Dendritic cells 
DTRF Drug and treatment related fever 
EBV Epstein-Barr virus 
EM Electron microscopy 
FluA Influenzavirus A 
FluB Influenzavirus B 
FN Febrile neutropaenia 
fNS Flocked nasal swab 
FUO Fever of unknown origin 
HCoV Human coronavirus 
HEV Human enterovirus 
HHV Human herpesvirus 
HMPV Human metapneumovirus 
HRV Human rhinovirus 
HSCT Haematopoiesis stem cell transplantation 
IFI Invasive fungal infections 
IL- Interleukin -  
JCV JC polyomavirus 
LBP LPS-binding protein 
LPS Lipopolysaccharides 
MBL Mannose-binding lectin protein 
MBL2 Mannose-binding lectin (protein C) 2  
mCD14 Membrane-bound CD14 
NHL Non-hodgkins lymphoma 
NPA Nasal pharyngeal aspirate 
PBMC Peripheral blood mononuclear cells 
PCR Polymerase chain reaction 
PCT Procalcitonin 
PIV 1-4 Parainfluenza virus 1-4 
PML Progressive multifocal leukoencephalopathy 
PML Progressive multifocal Leukoencephalopathy 
qPCR Quantitative PCR 
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RPMI 1640 Roswell Park Memorial Institute, media formula 1640 
RS Reed-Steinberg  
RSV Respiratory syncytial virus 
RSV Respiratory syncytial virus 
sCD14 Soluble CD14 
SNP Single nucleotide polymorphism 
TLR- Toll-like receptors 
TNF-α Tumour necrosis factor- alpha 
VZV Varicella-zoster virus 
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1 PREFACE 
 
 
The human immune system is made up of a complex network of cells and molecules, 
each with an independent function yet, collaborating to achieve protection against 
invading pathogens we encounter daily and, developing a sustained memory to prevent 
infections when we next encounter the same pathogen again.  It would be fair to say 
that ‘the whole is greater than the sum of the individual parts’ and a delicate balance is 
maintained between preventing infections and excessive tissue damage from pro-
inflammatory responses.  
 
Unfortunately, in situations where abnormal proliferation of malignant cells has 
occurred, the cytotoxic treatment strategy undertaken has an equally deleterious effect 
on cells of the immune system as well as the target malignant cells.  Regardless, there is 
little recourse than to proceed with the treatment and deal with the consequences as 
they appear.  A large proportion of which are infection related but the aetiology of the 
remaining is relatively unknown and suggested to be drug or tumour fever, in the 
absence of microbiological findings. 
 
This thesis attempts to elucidate the aetiology of fever and infection susceptibility in the 
neutropaenic patient.  In the first section of this thesis, an introduction to 
haematological disorders, infectious complications following cytotoxic chemotherapy, 
viral detection methods and immune alterations observed in this patient group is 
presented.  This will lead on to a brief description of the materials and methods used, as 
well as, presentation of the main findings and concluding discussion of these results in 
relation to the triple goals of (1) discovering the contribution viruses to febrile 
neutropaenic episodes, (2) discovering the aetiology of febrile neutropaenic episodes 
with no attributable cause and, (3) ascertaining the role of an acute phase protein in 
infection susceptibility.   
 
The intricate interactions involved in maintaining daily life as we know it is far more 
complex and it is not the intent of this thesis to tease it apart.  A snapshot, describing 
observations in a particular time and space is perhaps a more apt depiction of the work 
presented here.  A small, yet hopefully important, piece of the puzzle is presented for 
your deliberation. 
 
 
 
 
 
 
 
Michelle Wong 
12 March 2012 
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2 INTRODUCTION 
 
2.1 THE IMMUNOCOMPROMISED HOST  
 
2.1.1 Haematological malignancies 
Immune suppression can be attributed to many causes but will be limited to patients 
with haematological malignancies in this thesis.  Common forms of haematological 
malignancies in adults can be broadly classified into leukaemias, lymphomas and 
multiple myelomas.  
 
Leukaemias are a group of diseases exemplified by the neoplastic accumulations of 
malignant bone marrow precursor cells.  Depending on the precursor cells, myeloblasts 
or lymphoblasts, the leukaemias are further classified into acute/chronic myeloid 
leukaemia or acute/chronic lymphoblastic leukaemia. Abnormal proliferation of these 
cells can lead to bone marrow failure by suppressing normal haematopoiesis which 
leads to anaemia, neutropaenia and thrombocytopaenia.  Organ infiltration of these 
malignant cells can also occur if they gain entry into the circulatory system (Hoffbrand, 
2006).  In the adult patient, acute myeloid leukaemia (AML) is more common than 
acute lymphoid leukaemia (ALL) and the reverse is true for children. 
 
 Lymphomas are a highly heterogeneous group of disorders caused by the accumulation 
of mature lymphocytes in the lymph nodes, hence the classic clinical feature of 
lymphoadenopathy.  Occasionally, these malignant cells may enter the blood during the 
leukaemic phase or infiltrate other organs as well.   Lymphomas can be further 
classified into two large groups based primarily on the presence of Reed-Steinberg (RS) 
cells.  RS cells are found in Hodgkins disease and all other lymphomas without RS 
cells are termed ‘Non-Hodgkins Lymphoma’ (NHL).  RS cells observed in Hodgkins 
disease, which account for less than 10% of all lymphomas,   has been suggested to 
originate from B-cells with mutations which prevent synthesis of full length 
immunoglobulins (Hoffbrand, 2006).  Non-Hodgkins lymphoma (NHL), on the other 
hand, describes a larger, less well-defined and more variable diseases.  Classification of 
diseases in NHL is inherently tricky but consensus achieved with the Revised 
European-American Lymphomas classification (REAL) (Harris et al., 1994) and World 
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Health Organisation (WHO) (Vardiman et al., 2009) has helped with subdividing 
lymphomas based on immunophenotyping, cytogenetic and molecular characteristics.   
 
Multiple myeloma is a disease caused by neoplastic proliferation of bone marrow 
clonal plasma cells and is additionally characterised by lytic bone lesions and the 
presence of monoclonal immunoglobulins in serum and urine.   Located throughout the 
bone marrow, clumps of malignant plasma cells appear and thus the term ‘Multiple 
myeloma’.  Primarily an adult disease, the aetiology is relatively unknown although 
cytokines, for example IL-6 has been suggested to be a potent growth factor for 
multiple myelomas (Hoffbrand, 2006).  
 
2.1.2 General treatment strategies 
Targeting abnormal and prolific neoplasm, treatment strategies are generally curative 
and directed towards limiting the further growth and spread of the malignancy.  Most 
chemotherapeutic drugs fall into a few main categories; alkylating agents, 
antimetabolites, plant alkaloids, topoisomerase inhibitors and ‘antitumour antibiotics’.   
 
Alkylating agents act by attaching an alkyl group to a DNA base, usually the guanine 
base, leading to cross-linking of the DNA double-helix strands thus preventing further 
cell division.  Anti-metabolites are generally nucleoside analogues (purine or 
pyrimidine) that inhibit cell division and RNA synthesis by competing with intrinsic 
purines and pyrimidines.  Alkaloids derived from plants prevent normal microtubule 
function hence, halting cell division while topoisomerase inhibitors interfere with both 
transcription and replication of DNA by disrupting DNA unwinding and supercoiling.  
Lastly, ‘antitumour antibiotics’, so called because of their initial discovery in 
microorganisms, include a wide range of compounds for example, anthracyclines and 
DNA intercalators (Airley, 2009).  Monoclonal antibodies specifically targeting lysis of 
CD20+ B- lymphocytes has been used and is an approach away from generic inhibition 
of cell proliferation. 
 
Corticosteroids are sometimes included in combination to suppress potential 
inflammation  and has been reported to induce lymphocyte apoptosis (Zitvogel et al., 
2008)and dendritic cell (DC) dysfunctions.  Regardless of the drugs used, all of them 
exert their effect by interfering with cell division and DNA synthesis and these effects 
are seldom specific to the malignant cells only.  Bystander damage to other normally 
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rapidly dividing cells, for example, cells of the immune system and gut epithelial cells 
often occur, leading to further infectious complications which will be described in the 
ensuing chapters.   
 
2.1.3 Febrile neutropaenia in the iatrogenic immunosuppressed patient 
Neutropaenia is a common occurrence as a result of the cytotoxic chemotherapeutic 
treatment and is associated with increased risk of infections (Bodey et al., 1966).  
Variably defined, neutropaenia is said to have occurred when the absolute neutrophil 
count drops below 1x109 cells/ml of blood.  While an immunocompetent individual is 
able to present with a myriad of symptoms upon infection, with the immunosuppressed 
patient, fever is often the primary and only clinical sign of an infection.  Infectious 
complications can potentially have fatal consequences hence an occurrence of 
infection-related fever prompts empiric antimicrobial therapy and necessitates delays 
and disruptions in the chemotherapeutic treatment for the underlying haematological 
malignancy (Pizzo, 1999).  However, in 30%-55% of febrile neutropaenic episodes, no 
attributable cause for the fever can be ascertained using routine microbiological 
diagnostics and these are termed fever of unknown origin (FUO) (Hahn-Ast et al., 
2010, Pagano et al., 2011b, Viscoli et al., 2006).  Drug and tumour fever or, necrotic 
cell death as a result of the cytotoxic treatment could trigger fever just as well as 
infection thus the non-specificity of fever renders it an unreliable diagnostic marker for 
infection in this patient group.  The severity of infections in these patients has prompted 
studies evaluating biomarkers able to distinguish infection-related fevers from 
otherwise ‘sterile’ fevers.  C-reactive protein (CRP) (Koivula et al., 2011, Manian, 
2012, Sakr et al., 2008), pentraxin 3 (Juutilainen et al., 2011) and procalcitonin (PCT) 
(Koivula and Juutilainen, 2011, Massaro et al., 2007, Ruokonen et al., 1999, Sakr et al., 
2008, Schuttrumpf et al., 2003, Simon et al., 2004) have been studied for this purpose, 
but their efficacy in identifying bacteraemia induced fevers is still not convincing.   
 
 
 
2.2 INFECTIOUS COMPLICATIONS 
 
Infections are common in the immunocompromised host (Pizzo, 1999, Menichetti, 
2010) in particular, patients that have undergone chemotherapy are at higher risk due to 
the disruption of mucosa (Duncan and Grant, 2003, Lehrnbecher et al., 1997, Meckler 
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and Lindemulder, 2009) and the use of indwelling devices like central venous and 
urinary catheter (Meckler and Lindemulder, 2009).  With more intensive treatment for 
haematological malignancies, the number of immunocompromised patients will 
undoubtedly increase.  Infections in the neutropaenic patients account for 50%-60% 
(Pagano et al., 2011b) of fever episodes and if left untreated, could lead to sepsis and be 
potentially fatal (Table 2.2-1).  Pre-emptive antimicrobial therapy  (Maschmeyer et al., 
2003, Wingard, 2004) has thus been the strategy taken but the emergence of antibiotic 
resistant bacterial strains has prompted many clinicians to exercise caution on the 
prolific use of these drugs (Akova et al., 2005, Krcmery and Beno, 2005).  By virtue of 
their neutropaenia, bacterial and fungal infections are most common, with viral 
infections only observed in low proportions of febrile episodes (Norgaard et al., 2006, 
Pagano et al., 2011a).  The skewed observation could also be a reflection of the 
microbiological focus in earlier investigations.  However, in this thesis, focus will be 
placed on viral infections with short discussions on bacteraemia and invasive fungal 
infections for an overall perspective of infectious complications in the 
immunocompromised host. 
 
Table 2.2-1. List of common infectious agents in the immunosuppressed host  (Meckler and 
Lindemulder, 2009, Menichetti, 2010)  
Bacterial Viral Fungal 
Gram-Positive Gram-Negative Blood-borne Respiratory  
Staphylococcus 
spp. 
Escherichia 
coli 
Cytomegalovirus Respiratory 
Syncytial virus 
Candida spp. 
Streptococcus 
spp. 
Pseudomonas 
aeruginosa 
Epstein-Barr 
virus 
Influenzavirus 
A and B  
Aspergillus spp. 
Enterococcus 
spp. 
Kleibsiella spp. BK virus Parainfluenza 
virus 
Zygomycetes 
Corynebacterium 
spp. 
Enterobacter 
spp. 
Herpes simplex 
virus 
Adenovirus Fusarium spp. 
Bacillus spp. Anaerobes Varicella-zoster 
virus 
 Scedosporium spp. 
Clostridium spp.  Enterovirus   
  Rotavirus   
  JC virus   
  Parvovirus B19   
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2.2.1 Bacteraemia 
Bacteria, as expected, represent the majority of identified pathogen in infectious 
complications faced by the neutropaenic host.  However, the proportions of Gram-
negative to Gram-positive bacteraemia have fluctuated over the decades (Ellis, 2008).  
Before the 1980s, Gram-negative bacteraemia especially species originating from the 
gastrointestinal tract typified by, E.coli, Kleibsella spp. and Pseudomonas spp. 
predominate.  The introduction of beta-lactam antibiotics led to diminishing Gram-
negative bacteria numbers and shifted the balance towards one where Gram-positive 
bacteraemia dominated.  Staphylococcus spp., coagulase-negative  Streptococcus spp. 
and Enterococcus spp. and more alarmingly, Streptococcus viridians were increasingly 
seen and have remained so till recently where Pseudomonas aeruginosa and 
Enterobacteriaceae have been increasingly documented (Cometta et al., 1996, Cometta 
et al., 2003, Kern et al., 1999, Klastersky et al., 2007, Mancini et al., 2008, Menichetti, 
2010, Viscoli, 2002, Viscoli et al., 2005, Wisplinghoff et al., 2003).   
 
The use of prophylactic antibiotics as pre-emptive treatment for the 
immunocompromised host has undoubtedly reduced bacteria-associated mortality.  
However, antibiotic resistant Strep. viridians, Enterococci spp. and E.coli have 
emerged due to excessive use of beta-lactam antibiotics and quinolones thus, judicious 
use of antibiotics is encouraged.   
 
2.2.2 Invasive fungal infections (IFI) 
Invasive fungal infections have been documented in 2%-40% of immunosuppressed 
patients with haematological malignancies and prolonged neutropaenia after 
chemotherapy (Bohme et al., 2009, Cuenca-Estrella et al., 2008, Hahn-Ast et al., 2010, 
Marr et al., 2002b, Martino and Subira, 2002, Muhlemann et al., 2005, Pagano et al., 
2006, Whimbey et al., 1987).  Candida spp. and Aspergillus spp. are most commonly 
implicated in invasive fungal infections but the proportions have varied through the 
years depending on the use of azole prophylaxis (Akova et al., 2005, Ellis, 2008, Hahn-
Ast et al., 2010, Krcmery and Beno, 2005, Marr, 2000, Marr et al., 2002a, Marr et al., 
2002b, Marr et al., 2000, Menichetti, 2010, Pagano et al., 2011a).  However, reduced 
susceptibility to azoles (ketoconazol, fluconazol and itraconazol) in non-albicans 
Candida spp. has been observed in some centres and is a growing concern (Krcmery 
   15 
and Babela, 2002).  The emergence of Zygomycetales, resistant to the latest 
antimicrobial treatments is also worrying.   
 
 
2.2.3 Viraemia 
Viral infections that are often self-limiting in the healthy individual can represent a 
larger threat to the immunocompromised host.  In the course of our lives, we would 
have encountered and overcome a multitude of viral infections but compromising the 
immune system, especially the T-lymphocytes targeting these virus places the 
immunocompromised host at great risk (Christensen et al., 2005, Hakim et al., 2009, 
Wade, 2006). 
 
2.2.3.1 Reactivation of latent viruses 
 
Herpesviruses 
Human Herpesviruses are members of the Family Herpesviridae and are linear dsDNA 
viruses and range in size from 125nm to 260nm.  The icosahedral capsid is enveloped 
with viral glycoprotein spikes on the surface and the variation in sizes is suggested to 
be due to variations in the tegument layer in between.   
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Table 2.2-2.  List of human herpesviruses commonly associated with the 
immunosuppressed host. (Adapted from (Philip E. Pellet, 2007)  
Designation Name Genome size 
(kbp) 
Human herpesvirus 1 
(HHV-1) 
Herpes Simplex virus 1 152 
Human herpesvirus 2 
(HHV-2) 
Herpes Simplex virus 2 155 
Human herpesvirus  3 
(HHV-3) 
Varicella-zoster virus  125 
Human herpesvirus  4 
(HHV-4) 
Epstein-Barr virus 172 
Human herpesvirus  5 
(HHV-5) 
Cytomegalovirus 230 
 
All human herpesviruses have the ability to remain latent in their natural hosts, taking 
on the form of closed circular molecules with the expression of only a small subset of 
genes during latency (Pellet and Roizman, 2007).  The mechanism of reactivation from 
latency varies between the virus species but in the immunosuppressed host, the altered 
immune system especially depletion of cellular immunity, is the most likely 
explanation.   
 
Herpes simplex virus reactivation can manifest as ulcers in the mucocutaneous zones 
and can be difficult to distinguish from chemotherapy-related mucositis (Hakim and 
Shenep, 2010).  Varicella-zoster (VZV) infections in adults with haematological 
malignancies are reactivated from earlier infections (Wade, 2006, Locksley et al., 1985) 
while VZV naïve patients should be wary of contracting the infection from the 
community and vaccination of either themselves or close familial contacts is advised.  
Epstein-Barr virus residing in B-lymphocytes can proliferate in the absence of T-
lymphocyte control and can lead to post-transplant lymphoproliferative disease (PTLD) 
(Rickinson and Kieff, 2007).  Last, and certainly not least, cytomegalovirus 
reactivations are significant in the immunocompromised host with impaired T-
lymphocyte immunity and account for substantial morbidity and mortality in these 
patients (Hakim and Shenep, 2010).  The disease manifests as pneumonitis, 
enterocolitis, hepatitis, encephalitis, cystitis, nephritis, bone marrow suppression and 
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multi organ system failure (Boeckh et al., 2003, Hakim and Shenep, 2010, Hebart and 
Einsele, 2004, Nguyen et al., 2002, Wade, 2006).  Of importance in patients 
immunesuppressed for HSCT procedures, the relevance of herpesviruses in 
chemotherapy-induced neutropaenic patients has not been clearly established. 
 
Adenovirus 
Human Adenoviruses are dsDNA (26-45kbp), non-enveloped viruses of the family 
adenoviridae.  They are medium sized viruses, approximately 90nm in diameter, with 
fibres projecting from the vertices of the icosahedral capsid. Since its discovery in 
1953, more than 51 human adenovirus serotypes have been identified, based on their 
resistance to neutralisation by antisera to other known human adenovirus (De Jong et 
al., 1999, Hierholzer et al., 1991).  These serotypes can be further categorised into 
seven serogroups (A-G) based on their ability to agglutinate red blood cells (ICTV, 
2009 ). 
 
Aside from Group B adenoviruses, all other adenoviruses bind to the plasma membrane 
Coxsackie B virus and adenovirus receptor (CAR).  Ubiquitous expression of CAR in 
epithelial cells of various tissue types, gastrointestinal tract, respiratory tract, explains 
the variation of symptoms observed with adenovirus infection.  Human adenovirus has 
been associated to a variety of clinical syndromes, upper and lower respiratory disease, 
conjunctivitis, gastroenteritis, haemorrhagic cystitis, hepatitis, to name a few.   In 
immunocompetent patients, adenovirus usually causes a mild self-limiting acute 
infection but have the ability to persist in the adenoid vegetations of the nasopharynx 
and in tonsils and,  B lymphocytes have been observed to harbor viral DNA in a non-
productive state (Horvath et al., 1986, Neumann et al., 1987, Rajcani, 2007).   Secretion 
of subgroup c adenovirus into faeces long after resolution of the initial acute upper 
respiratory tract infection (Adrian et al., 1988, Fox et al., 1969, Fox et al., 1977) and the 
recovery of Adv3 from the tears of patients, 10 years after acute conjunctivitis (Kaye et 
al., 2005) are further evidence for the persistence of AdV. 
 
In post-transplantation immunosuppressed patients, adenovirus can cause fatal 
infections resulting in hepatitis abnormalities, pneumonia and encephalitis (Bowles and 
Vallejo, 2003, Krilov, 2005, Wold and Horwitz, 2007).  Interestingly, adenovirus 
strains identified in the immunocompromised patient were no different from ubiquitous 
serotypes prevalent in patients with other, less serious illnesses suggesting that the 
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immunocompromised host may be no more commonly infected, rather that the outcome 
of the infection more severe (Wold and Horwitz, 2007).  In liver transplant patients, 
reactivation of latent adenovirus in the donor organ as a source of adenovirus infection 
has also been documented (Cames et al., 1992).  Deaths from adenoviraemia is closely 
linked to recovery of T-lymphocytes function following immunosuppression 
(Chakrabarti et al., 2002, Heemskerk et al., 2005, Kampmann et al., 2005, van Tol et 
al., 2005) and to some extent adenoviral loads in peripheral blood (Claas et al., 2005).  
The relevance of adenoviral infections in the non-transplant immunesuppressed patient 
is less studied.   
 
2.2.3.2 Opportunistic viral infections 
 
Parvovirus B19 
Parvovirus B19 was the first known human virus in the parvoviridae family.  It is a 
small (18-26nm), non-enveloped virus with a linear ssDNA encapsulated in an 
icosahedral capsid.  Human transmission of the virus is suggested to be via aerosol 
inhalation, faecal-oral route and via infected blood products.  Target cells for 
parvovirus B19 are the erythroid progenitor cells, through the P antigen receptor, 
located in the bone marrow although, occasionally the virus infects leukocytes 
(especially neutrophils) (Mustafa and McClain, 1996).  
 
Viremia is generally an acute, bi-phasic event (Anderson et al., 1985), with non-
specific influenza-like symptoms, including fever, malaise and myalgia (Burns and 
Parrish, 2007) and erythrocyte aplasia.  Acute infection with parvovirus B19 causes the 
childhood erythema infectiosum (fifth’s disease).  Peak occurrence of parvovirus B19 
infections are seasonal and occur in late winter, spring and summer (Young, 1995) and 
are often spread among schoolchildren and sibling-sibling transmission.  Upon 
clearance of the acute infection, individuals develop long-lasting antibody-mediated 
immunity (Srivastava et al., 1990). 
 
Immunocompromised patients as a result of chemotherapy or immunosuppressive 
drugs may develop chronic parvovirus B19 infection, resulting in prolonged 
cytopaenia, especially anaemia that interferes with their planned course of 
chemotherapy (El-Mahallawy et al., 2004, Lindblom et al., 2008, Soliman Oel et al., 
2009).  
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Polyomavirus 
The two human polyomaviruses, JC virus (JCV) and BK virus (BKV) were originally 
isolated from immunocompromised hosts in 1971 (Gardner et al., 1971, Padgett et al., 
1971) and their relevance in this patient group remains although the mechanism of 
action may still be unclear.  Polyomaviruses are non-enveloped particles 40-45nm in 
diameter, with a covalently closed circular dsDNA approximately 5kbp long.  
 
Cell receptors for BKV and JCV are not completely established but BKV has exhibited 
tropism towards gangliosides and N-linked glycoproteins containing sialic acid 
moieties (Dugan et al., 2005, Low et al., 2006, Seganti et al., 1981).  JCV entry into the 
cell is however suggested to be via clathrin-mediated endocytosis after binding to 
α(2,6)-sialic acid and 5HT2A serotonin receptor (Elphick et al., 2004) .  These two 
viruses are ubiquitous in most populated populations, as evidenced by 
seroepidemiology studies (Knowles et al., 2003).  Antibodies remain throughout life 
but can fluctuate in titre although, it is unknown if it is a result of reinfection or 
reactivation infections.  Maintenance of chronic viral infection is another biological 
characteristic of JCV and BKV, with viral shedding in the urine from a chronically 
infected kidney.  Aside from urine and the primary organ of infection, both viruses 
have been detected in peripheral blood (Azzi et al., 1996) and in some studies with the 
American and European populations, it has been estimated that 2% to 3% of the with 
no underlying disease carry JCV DNA (Dubois et al., 1997). 
 
BKV-associated haemorrhagic cystitis (Leung et al., 2001, Silva Lde et al., 2010) and 
progressive multifocal leukoencephalopathy (PML) as a result of JCV reactivation are 
potentially severe complications in the immunocompromised host especially patients 
on immunosuppressive drugs for graft protection.  Regardless of the virus species, 
either reactivation, chronic or opportunistic infection of polyomavirus has an impact on 
the immunocompromised host as it might delay chemotherapy treatment for their 
underlying disease or necessitate reduction of immunosuppressive drugs required for 
engraftment post-transplant. 
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Respiratory virus infections 
Respiratory viral infections are widespread in the community and are therefore easily 
spread to imunosuppressed patients with underlying haematological malignancies.  
General characteristics of viruses commonly implicated in respiratory infections are 
listed in table 2.2-3.  The term community acquired respiratory virus (CRV) infections 
is apt as the patient generally acquires the disease from family members or medical 
staff in the hospital (Bowden, 1997, Couch et al., 1997, Harrington et al., 1992, 
Ljungman, 1997, Nichols et al., 2001, Shah and Chemaly, 2011, Whimbey et al., 1997, 
Englund et al., 2011, Englund et al., 1999, Hakim and Shenep, 2010, Wade, 2006).  
Influenzaviruses (A and B), respiratory syncytial virus, parainfluenzaviruses (1-2), 
adenoviruses and, possibly rhinoviruses, are the most common CRVs (Bowden, 1997, 
Couch et al., 1997). 
 
Table 2.2-3. General characteristics of respiratory viruses 
Family Virus species Genome Genome 
size 
Envelope Host receptors 
Picornaviridae Human 
rhinovirus 
(+) RNA ~7kb No ICAM-1 or LDL  
Paramyxoviridae Respiratory 
syncytial virus 
(-) RNA ~15kb Yes Glycosaminoglycan 
Paramyxoviridae Parainfluenza 
virus 1-4 
(-) RNA ~15kb Yes Sialic acid 
Paramyxoviridae Human meta- 
pneumovirus 
(-) RNA ~13kb Yes unknown 
Orthomyxoviridae Influenzavirus 
A and B 
Segment,  
(-)RNA 
~15kb Yes Sialic acid 
Coronaviridae Human 
coronavirus 
(+) RNA ~30kb Yes Aminopeptidase N, 
9-o-acetylated 
siaclic moieties or 
angiotensin-
converting enzyme 
2. 
Adenoviridae Human 
adenovirus 
Linear 
dsDNA 
~36kbp No CAR  
Parvoviridae Bocavirus Linear 
ssDNA 
~6kb No Unknown 
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Human metapneumoviruses and bocaviruses have also been recently identified in 
symptomatic transplant recipients (Boivin et al., 2002, Koskenvuo et al., 2008, Peret et 
al., 2002, Schenk et al., 2007) although their relevance is unclear.   In temperate 
countries, the virus species responsible for respiratory infections vary throughout the 
year (Fig. 2.2-1) and the seasonality of CRV infections in the community is reflected in 
the immunocompromised host as well. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
An immunocompetent individual usually clears the infection with mild symptoms 
whilst prolonged infection with RSV (Craft et al., 1979, Fishaut et al., 1980, Hall et al., 
1986, Harrington et al., 1992, King et al., 1993, McIntosh et al., 1984),  parainfluenza-3 
(Fishaut et al., 1980, Gelfand et al., 1983, Josephs et al., 1988) and influenza A (Craft 
et al., 1979) occurs in the immunocompromised patient (Couch et al., 1997).  In 50%-
70% of immunocompromised patients (bone-marrow transplant or induction 
chemotherapy for leukaemia) with CRV develop pneumonia, with mortality ranging 
from 9% to 45% (Bowden, 1997, Couch et al., 1997, Harrington et al., 1992, 
Ljungman, 1997, Whimbey et al., 1997).  Thus, prompt identification of the respiratory 
viral pathogen is critical for the initiation of specific antiviral therapy or even, the 
potential delay of immunosuppressive therapy or transplantation to avert the severe 
consequences of CRV infections.  
Spring Summer Winter Autumn 
Adenovirus 
Coronavirus 
Influenzavirus 
Parainfluenzavirus 
Rhinovirus 
Respiratory 
syncytial virus 
Figure 2.2-1. Seasonal variations of community acquired respiratory 
viruses.  Adapted from (Englund et al., 2011) 
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Many other viruses have been associated with the immunocompromised host, 
enterocolitis from rotavirus infection (Stelzmueller et al., 2007) and gastroenteritis from 
norovirus infection in HSCT recipients (Roddie et al., 2009, Saif et al., 2011).  The 
degree and duration of immunosuppression are major risk factors for reactivation of 
latent viral infections and opportunistic viral infections. 
 
2.2.4 Polymicrobial infections 
In 8% to 25%  of blood bacteraemic infections, polymicrobial infections are 
documented in treatment-induced immunosuppression (Gupta et al., 2010, Norgaard et 
al., 2006, Rolston et al., 2007, Cometta et al., 1996, Del Favero et al., 2001, 
Giamarellou et al., 2000, Gonzalez-Barca et al., 1999, Jacobson et al., 1999, Klastersky 
et al., 2007, Peacock et al., 2002, Rossini et al., 2005, Sanz et al., 2002, Sigurdardottir 
et al., 2005, Whimbey et al., 1987).  These could be co-infections with more than one 
species of bacteria or, co-infections of bacteria with fungal or viral infections (Cometta 
et al., 1996, Del Favero et al., 2001, Giamarellou et al., 2000, Gonzalez-Barca et al., 
1999, Jacobson et al., 1999, Klastersky et al., 2007, Peacock et al., 2002, Rossini et al., 
2005, Sanz et al., 2002, Sigurdardottir et al., 2005, Whimbey et al., 1987).  Although 
the definition of polymicrobial infections is not standardised, it is apparent through the 
years that polymicrobial infections do occur.  The relevance, other than indicating a 
more severe immunosuppression, is however, debatable.  Regardless, a better 
estimation of the microbial load in this vulnerable group could enable a better informed 
treatment of infections.      
 
2.2.5 Microbial translocation 
A large population of bacteria, in the order of 1012 /mm, resides within the estimated 
200 m2 human intestinal lumen surface (Ellis, 2004, Balzan et al., 2007) yet an 
immunocompetent individual is relatively disease-free due to an intact mucosal 
immunological defence.  Disruption of the gut mucosa, particularly the enterocytes, as 
a result of cytotoxic treatments renders the immunucompromised host at risk for the 
translocation of bacteria and bacteria-products into the circulatory system. 
 
The two major routes of bacterial translocation are (1) transcelluar, through the 
enterocytes and (2) paracellular, using the tight junctions. (Balzan et al., 2007, Ellis, 
2004).  Structural damage to enterocytes as a result of cytotoxic chemotherapy suggests 
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that the paracellular route of translocation predominates in patients undergoing 
treatment for haematological malignancies (Gasbarrini and Montalto, 1999, Keefe et 
al., 2000).  Thereafter, the principal pathway for entry into systemic circulation is via 
the lymphatic enteric drainage (Deitch, 2002), followed by draining via the intestinal 
subepithelial capillaries (Balzan et al., 2007, Moore et al., 1991).    
 
Lipopolysaccharides (LPS) and some glycopeptides found on surfaces of commensal 
intestinal bacteria are pyrogens and potent activators of pro-inflammatory response via 
Toll-like receptor 4/MDA-2 complex (Poltorak et al., 1998).  LPS in itself, even in the 
absence of live bacteria is sufficient to initiate the pro-inflammatory cascade and cause 
fever.  The binding receptor of the LPS monomer is sCD14, which activates pro-
inflammatory response by presenting LPS monomers to TLR4 directly or via mCD14 
(Hailman et al., 1996) and initiating the release of cytokines such as Tumour necrosis 
factor- alpha (TNF-α) and interleukins 1 and 6 (IL-1, IL-6).  sCD14 however, has an 
alternate role of inhibiting excessive pro-inflammatory cytokine release by shuttling 
LPS to circulating lipoproteins, where they eventually cleared.  The same can be said of 
the LPS-binding protein (LBP) which alternately acts as a catalyst accelerating LPS 
binding to sCD14 (Jack et al., 1997, Yang et al., 2002, Knapp et al., 2003, Fan et al., 
2002) as well as promoting the clearance of LPS via binding to lipoproteins (Wurfel et 
al., 1994, Kitchens et al., 2003).  The dual bioactivity roles of sCD14 and LBP ensure 
that effective clearance of bacterial pathogens at the local site of infection is not 
achieved at the expense of unnecessary tissue damage through excessive stimulation of 
circulatory pro-inflammatory cytokines. 
 
The presence of flagellin, another bacterial product is also capable of initiating a pro-
inflammatory cascade via Toll-like receptor 5. Thus, in the absence of bacteraemia, 
patients with microbial translocation may still develop febrile symptoms, indicative of 
an infection.  Some early studies had suggested that translocation of microbial products 
might explain fever in chemotherapy-immunosuppressed patients (Gunther et al., 1995, 
Harris et al., 1984, McCartney et al., 1987, Tancrede and Andremont, 1985) although 
their findings are in some cases limited by their use of faecal bacterial cultures as 
indicators for microbial translocation.  The degree of mucosal disruption would 
determine if it would be the whole bacteria or simply bacterial products that would 
translocate and the use of faecal bacterial cultures will not be able to reflect the latter 
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situation.  Assays targeting the LPS systemically, together with the faecal cultures 
would allow better estimation.    
 
 
 
2.3 VIRAL DETECTION METHODS IN IMMUNOSUPPRESSED PATIENTS  
 
Viral detection methods have developed much over the years and there are often more 
than one method that can be used for any viral species, but the focus here will be the 
relevance in the immunocompromised patient.  In general, viral detection methods fall 
into one of the following categories: (1) Virus culture and direct visualisation; (2) Viral 
antigenic detection; (3) Serology and; (4) Nucleic acid detection.  Although discussed 
separately, virus culture and visualisation is often coupled with viral antigenic detection 
for improved specificity. 
 
2.3.1 Virus culture and direct visualisation 
The use of virus culture for detection has limited use despite its standing as a ‘gold 
standard’.  In general, cytopathic effects (CPE) in the cell monolayer are used to 
indicate presence of viruses but this is rather non-specific.  Although well controlled in 
the laboratory setting, cultured cells die off from a multitude of reasons and can 
sometimes be mistaken for CPE.  Virus tropism is another major flaw in the virus 
culture system which means that a large array of immortalised cell lines needs to be 
maintained.  The use of primary cells, able to support a wider range of viruses is a 
possibility if the cost of maintaining fresh cultures can be overcome.   
 
Histological investigations with light microscopy, used in conjunction with virus 
culture can be useful in the detection of some viruses, for example with rabies virus 
where viral inclusion bodies, termed negri bodies are observed in the cytoplasm of 
infected nerve cells.  However, such specific cellular changes are not always present in 
many viral infections and the use of electron microscopy for direct visualisation of the 
virus is preferred.   
 
Electron microscopy (EM) has long been the hallmark of virus detection methods.  The 
large magnifications achievable by EM afford the observer an opportunity to actually 
view the virus particle, which would otherwise be an abstract object.  To a well trained 
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operator, virus identification can be performed directly from clinical samples.  
However, the major limitation of EM is the lack of sensitivity with typically, 105 to 106  
virus particles/mL are required for reliable visualisation.  Virus culture prior to EM 
visualisation is a way to circumvent the limitation in sensitivity but suffers from the 
drawbacks as mentioned above.  Even when an image of the virus is captured, the 
information gleaned would be restricted in the presence of commensal viral populations 
for example in gastrointestinal tract or an immunosuppressed patient highly susceptible 
to a multitude of viral infections.  Nonetheless, EM has been and still is, extensively 
used to investigate virus structures and in situations where speed and sensitivity is not 
crucial. 
 
2.3.2 Viral antigaenic detection 
Antigens present on viruses are the targets of these methods which improve on the 
limited specificity of direct visualisation methods. The most commonly practiced 
technique is immunofluorescence coupled with microscopy.  Antibodies specific to 
viral antigens are fluorescently labeled so that one may visualise the location of the 
virus particle within the cell.  Evidently, the specificity of the assay is highly dependent 
on the choice of antibodies directed towards the viral antigen.  Although the technique 
has the ability to improve specificity, sensitivity is still limited.   
 
2.3.3 Serology 
The bulk of virus detection methods are serology based, detecting antibodies developed 
upon exposure to viruses.  These include classical methods, complement fixation tests 
(CFT), Haemagglutination inhibition assays (HIA) and neutralization tests as well as, 
‘newer’ techniques for example, western blots, and  enzyme linked immunosorbent 
assays (EIA). A natural primary humoural response occurs when we encounter viral 
antigens and this is generally specific for the viral species.  Cross-reactivity to viral 
antigens does of course occur for example with some of the flaviviruses.  The target 
molecules in serological assays are usually the IgM or IgG based on the principle that 
IgM titres rise rapidly in an acute infection, followed by an increase in IgG after a 
couple of weeks but as in all things biology, there are always exceptions to the rule.  
With respiratory viral infections, many viruses produce clinical disease before the 
appearance of antibodies.  Another inherent difficulty with these methods is in defining 
a threshold which constitutes a rise from background.  This is commonly determined by 
comparing antibody levels from samples taken during the acute phase with another 
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taken during the convalescent phase.  Aside from epidemic situations, there is limited 
utility in identifying the causative virus after cessation of the course of infection in an 
individual patient.  An immunocompromised patient, especially one with impaired B-
lymphocyte cells and function, is unlikely to produce a strong enough humoural 
response for reliable detection and transfusions may blur IgG boosting.  
 
2.3.4 Molecular detection 
Molecular methods for viral detection are the latest methods in the toolbox of the 
virologist.  Nucleic acid based detection methods are growing in popularity as it offers 
improved specificity and sensitivity.  The dropping costs in the running of these assays 
in recent years have made these methods a highly attractive option.  Today, nucleic acid 
detection methods are almost synonymous with PCR but it is important to remember 
other methods which can be used too, Southern blots, Northern blots and Nucleic acid 
based amplification (NASBA).  Taking the basic ideas forward, microarrays capable of 
screening hundreds of viruses have been developed (Wang et al., 2002) and sequencing 
is becoming a viable option for virus detection in view of the rapid development of 
deep sequencing instrumentation (Beerenwinkel and Zagordi, 2011).   
 
PCR is a highly specific and sensitive tool suitable for use in the detection of viruses.  
The rapid turnaround from sampling to result is extremely attractive for clinical 
applications where treatment modalities can be tailored.  PCR sensitivity is based on 
the highly efficient amplification of target sequences with a DNA polymerase, Taq 
polymerase while its specificity is dependent on the design or primers that selectively 
bind to the target sequence.  Used together with a fluorescent probe, additional 
quantitation ability and specificity is conferred but more importantly, amplification of 
the target sequence can be monitored in real-time as a result of the fluorescent signal 
emitted from the cleaved probe.  Together with improvements in equipment, PCR 
offers specific, sensitive and rapid results.  
 
The sensitivity of PCR is however, both its blessing and its curse.  Theoretically 
capable of detecting single copies of viral nucleic acids, it offers results beyond any of 
the other methods can but the relevance of finding minute quantities of viruses which 
may or may not be viable is debatable.  The dogma that some body fluids, for example 
cerebrospinal fluids, should be sterile has been used to justify the definition of viral 
infection when virus nucleic acid is detected, and rightly so.  This assumption does not 
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holdup in respiratory secretions where aerosolised viral particles may be encountered, 
or in blood samples of patients harbouring latent viral infections.  In theory, a viral 
infection is said to have occurred if even a single cell is infected but this does not 
constitute a symptomatic disease and better associations with viral nucleic acid copy 
numbers are required.  PCR contamination, as a result of remnant DNA products or 
simply from the sampling procedure would also be amplified along with the target virus 
and could also result in misleading information.  
 
Microarrays based on the hybridisation with probes immobilised on a slide, build on the 
specificity of PCR and enable high throughput screening against large panels of virus 
species.  Prior knowledge of viral genome sequences is necessary for the design of 
good probes and is also the intrinsic flaw of the technique and one is limited by the 
current sequence database.  Next generation deep sequencing platforms attempt to 
address this flaw with the promise of unbiased high throughput sequencing, enabling 
detection of true unknown viruses.  The primary strength of deep sequencing lies in the 
increased coverage of each target sequence but more importantly, the ability to 
sequence unanticipated sequences on account of the unbiased sequencing reaction.  In 
this way, sequence readouts are theoretically possible for every available nucleic acid 
sequence in the sample.  This is thus potentially the method of choice for the detection 
of true unknown viruses.  Of course, in the presence of an overwhelming amount of 
sequence data there is still a possibility of dismissing unusual sequences, and herein, 
the age-old requirement of experience might help, or not.   
 
In the immunosuppressed patient, molecular detection of viruses might be the most 
cost-effective option since serological assays are less useful due to their 
immunosuppression and frequent transfusions.  
 
 
2.4 IMMUNE ALTERATIONS IN THE IMMUNOSUPPRESSED HOST 
 
Despite encountering microorganisms daily in our lives, we do not fall ill more 
frequently and the immune system has a large part to play in our defence against 
microbial diseases.  The immune system however, is made up of many components, 
each working individually but still in cohort with each other.  The complexity of 
interactions is maintained in an inter-dependent balance, the disruption, for example in 
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the case of the immunosuppressed host, invariably increases susceptibility to infections.  
In general, the immune system can be divided into two arms; (1) the adaptive immune 
system and (2) the innate immune system.  They are so named to reflect the typical 
roles they play.  Cytotoxic chemotherapy treatment is necessary for the treatment of the 
underlying haematological malignancy but naturally also depletes the cells required in 
the immune system (Lehrnbecher et al., 1997).  This effect will be discussed in further 
detail in the following sections. 
 
 
2.4.1 Adaptive immune system 
 
2.4.1.1 T-lymphocytes 
Chemotherapy dose regimen administered for the treatment of the underlying 
haematological malignancy naturally plays a central role in degree of T-cell 
immunosuppression and the rate of T-cell recovery (Boldt et al., 1984, Cheson, 1995, 
Hersh et al., 1971, Kraut et al., 1990, Layward et al., 1981, Strender et al., 1981, Urba 
et al., 1989, Weiner and Cohen, 2002, Zitvogel et al., 2008).  Subtle difference however 
exist in the manner the two T-cell subsets (CD4+ and CD8+) respond to the cytotoxic 
agents.  CD4+ T-cells are not only depleted to a larger extent, recovery is also slower 
than those of CD8+ T-cells (Mackall et al., 1997, Mackall et al., 1994).  Further, fewer 
regenerated CD4+ T-cells are of the ‘naïve’ CD4+ phenotype but rather predominantly 
bear signs of activation and belong to the ‘memory’ CD4+ phenotype (Haining et al., 
2005, Mackall et al., 1994).  Age is inversely correlated to the proportions of ‘naïve’ 
phenotype CD4+ T-cells regenerated and this presumably reflects diminished thymic 
activity with age (Borella et al., 1972, Mackall et al., 1994, Storek et al., 1995, 
Weinberg and Parkman, 1995) although the rapid regeneration of CD8+ T-cells suggest 
that a thymic-independent pathway for T-cell regeneration might also play a role.  
Regardless, even if T-cell numbers are recovered, they are of a more restricted 
repertoire.  Dysfunction of regenerated T-cells have also been reported (Borzy and 
Ridgway, 1989, Chung et al., 1977, Katz et al., 1987, Layward et al., 1981, Magrath 
and Simon, 1976) and it is clear that these cytotoxic drugs not only deplete the existing 
T-cells, a profound effect on the change in their phenotype and function occurs as well.  
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2.4.1.2 Immunoglobulins 
Sub-optimal or absent immunoglobulins could predispose the immunosuppressed 
patient to infection from encapsulated bacteria, especially Streptococcus  pneumoniae 
and has prompted the introduction of  replacement therapy with commercial 
immunoglobulins (Abrahamsson et al., 1995, Alanko et al., 1992, Borella et al., 1972, 
Hitzig et al., 1976b, Hitzig et al., 1976a, Katz et al., 1987, Reid et al., 1977).  Patients 
undergoing haematopoietic stem cell transplantation (HSCT) are particularly at risk due 
to the intensity of their cytotoxic treatment.  Following HSCT, mature B-cells are 
effectively depleted (Baumgartner et al., 1988, Storek et al., 2001) but circulating IgG 
levels drop slowly due to their long half-life in serum (Cohen and Freeman, 1960) and, 
survival of plasma cells even after myelodepletion (van Tol et al., 1996).  In time, 
plasma cells would disappear resulting in a loss of protective antibodies against 
pathogens the patient had encountered previously (Wahren et al., 1984, Ljungman et 
al., 1990).  Acute lymphoblastic leukaemic patients treated with high intensity regimes 
have also been associated with low level of immunoglobulins (Abrahamsson et al., 
1995) and have prompted the initiation of re-vaccination post treatment in order to 
restore humoural immunity as soon as possible (Patel et al., 2007a, Patel et al., 2007b).   
 
However, suboptimal response to immunisation has also been observed if intensive 
chemotherapeutic regimes had been administered (Feldman et al., 1988, Alanko et al., 
1992, Borella et al., 1972, Hitzig et al., 1976b, Hitzig et al., 1976a, Katz et al., 1987, 
Layward et al., 1981, Ridgway et al., 1991, Weisman et al., 1987, Borella and Webster, 
1971, Rautonen et al., 1986).  In one study, low protective antibodies to measles and 
poliovirus were observed even one year after completion of therapy (Smith et al., 
1995).  Thus, antibody levels may be depressed long after cytotoxic therapy from the 
loss of pre-existing B-cells, slow B-cell regeneration and loss of supporting cells, for 
example CD4+ T-cells, which are essential for B-cell activation.   
 
2.4.2 Innate immune system 
The ‘ancient’ arm of the immune system, components of the innate immune system is 
normally the first to deal with an invading pathogen.  Utilising both cellular and 
acellular components, pathogens are inactivated early to prevent further spread.    
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2.4.2.1 Cellular compartments 
Cell that make up this component include macrophages, monocytes, NK cells and the 
granulocytes (neutrophils, eosinophils and basophils).  Early establishment that the 
depth and duration of neutropaenia is associated with serious bacterial infection 
(Schimpff et al., 1971, Bodey et al., 1966) has led to the use of absolute neutrophil 
counts as a measure of immunosuppression in this patient group (Freifeld, 1993, Pizzo, 
1993, Chanock and Gorlin, 1996).  Of course the quantity and quality of the other 
phagocytic cells (Losito et al., 1978, Hersh et al., 1966) are also invariably affected by 
the cytotoxic treatment but too few studies have been published that therapy induced 
neutropaenia remain the most important factor in infection risk (Freifeld, 1993, Pizzo, 
1993). 
 
In addition to depletion in numbers, neutrophil dysfunction after exposure to cytotoxic 
drugs has been reported in in vitro studies.  Neutrophils isolated from healthy 
volunteers showed impaired superoxide generation, microbiocidal activity and 
phagocytosis (Vaudaux et al., 1984, Whittaker et al., 1975, MacFadden et al., 1985, 
Pruzanski et al., 1983, Pickering et al., 1978, Hara et al., 1990).  Ex vivo studies with 
neutrophils isolated from lung cancer patients have also demonstrated reduced 
superoxide generation activity and reduced Fc receptor expression upon treatment with 
antineoplastic drugs (Ichinose et al., 1986).  It is however, important to acknowledge 
that in some instances, the underlying haematological malignancy has already 
contributed to defects in phagocytic cells.  Leucocytes from myeloid leukaemic patients 
display abnormal adhesiveness, migration, phagocytic function and killing activity of S. 
aureus and C. albicans (Lehrnbecher et al., 1997, Tornyos, 1967, Wilkinson et al., 
1975, Goldman and Th'ng, 1973).  Further, it is pertinent at this point to remember that 
the innate and adaptive immune cells are interdependent on each other for normal 
function.  Abrogation or dysfunction of T- and B- cells could have profound effects on 
the cells of the innate immune system as well. 
 
2.4.2.2 Acellular compartments 
The acellular compartments of the innate system circulate continuously and act as 
sentinels to detect the presence of microbes.  Generally thought of as unspecific, these 
molecules, mostly plasma proteins, are designed to recognise parts of microorganisms, 
bind to them and send off signals to recruit cells to either destroy the microbe or 
phagocytose them.  Prototypical molecules include members of the complement system 
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(classical-, alternate- and lectin- pathways), lysozyme, lactoferrin, fibronectin and the 
antimicrobial peptides.   
 
In an immunocompetent individual, their immediate early response serve to curtail 
infection and send out signals to recruit cellular components of the immune system and 
initiate a cascade of activity leading to the resolution of current infection and ‘memory’ 
for recurrent encounters.  In the absence of cellular components in the 
immunosuppressed patient, these plasma proteins potentially play a more important 
role in pathogen defence.   
 
Mannose-binding lectin (MBL) deficiency has indeed been associated with infections 
in an immunosuppressed patient group (Molle et al., 2006, Mullighan et al., 2002, Neth 
et al., 2001, Peterslund et al., 2001) and have been suggested for replacement therapy 
(Valdimarsson, 2003, Valdimarsson et al., 2004, Brouwer et al., 2009, Petersen et al., 
2006) although conflicting results remain (Frakking et al., 2011, Bergmann et al., 2003, 
Kilpatrick et al., 2003). Another classical acute phase protein, C-reactive protein (CRP) 
has been earlier suggested to be elevated in bacteraemia-related fevers in 
immunosuppressed patients (Hambach et al., 2002, Pihusch et al., 2006) however, other 
studies have found  no correlation.  In neutropaenic patients, procalcitonin (PCT) has 
also been demonstrated to discriminate bacteraemic-fevers from fevers of unknown 
origin (FUO) (Engel et al., 1999, Hambach et al., 2002, Pihusch et al., 2006, 
Schuttrumpf et al., 2003, Ruokonen et al., 1999) but several studies have highlighted 
the dynamic nature of PCT secretion (Engel et al., 1999, Jimeno et al., 2004, 
Fleischhack et al., 2000, Schuttrumpf et al., 2003). 
 
Dynamics of stimulation and secretion seems to be the crucial factor in the efficacy of 
these proteins as biomarkers for infection-related fevers.  This is hardly surprising 
since, the role of acute phase proteins are primarily pro-inflammatory, and transience, is 
the key to limit bystander cell/tissue damage at the expense of halting an infection.  
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3 AIMS OF THE THESIS 
 
The overarching aim of this thesis was to extend our knowledge of the aetiology of, and 
susceptibility to infection in the neutropaenic patient.  Here, we focus on an adult 
cohort rendered immunosuppressed after chemotherapy treatment for their underlying 
haematological malignancy.   
 
To achieve this aim, the thesis was designed in three parts : 
 
1. Detection and characterisation of viral infections via : 
 
a. Evaluation of sampling methodology for nasal secretions (Paper III) 
and; 
 
b. Development of molecular detection method to determine the prevalence 
of a select panel of viruses (Paper II).  
 
 
2. Determine the contribution of microbial translocation towards sterile febrile 
neutropaenic episodes classified as ‘Fever of unknown origin (FUO)’ (Paper 
IV). 
 
 
3. Investigate the role of innate host response for potential replacement therapy 
during neutropaenia (Paper I).  
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4 PATIENTS, MATERIALS AND METHODS   
 
4.1 PATIENTS AND INCLUSION CRITERIA 
 
The sub-studies/papers included in this thesis use material obtained from a single 
patient cohort but numbers in each paper vary depending on the material type and also 
on assay requirements.  During a 26 month period (January 2008 to February 2010), 
adult patients with haematological disorders at the Karolinska University Hospital, 
Stockholm were, after informed consent, included in a cross sectional study where the 
inclusion criterion was chemotherapy-induced neutropaenia (absolute neutrophil count 
≤500/mm3).  Patients that developed fever (auricular temperature >38.0˚C twice within 
an hour or ≥38.5˚C at one occasion) were sampled within 72 hours from fever onset, 
whereas patients without fever were sampled upon routine medical appointments 
during the neutropaenia episode.  The study was approved by The Regional Ethical 
Review Board in Stockholm, permit numbers 2007/1213-31/4 and 2008/1300-32.   
 
In total, 144 febrile neutropaenic episodes from 124 patients and 47 afebrile 
neutropaenic episodes from 39 patients were included in the whole study.   
 
 
4.2 MATERIALS 
 
Paper I, II and IV 
In addition to samples collected for routine clinical investigations, two vials of whole 
blood in EDTA-tubes and one vial of nasal pharyngeal aspirates (NPA) in 2-3mL of 
saline were collected within 72 hours from the onset of neutropaenic fever or at a 
routine scheduled visit for neutropaenic patients without fever.  A 150µL aliquot of 
whole blood was set aside at room temperature for flow cytometry analysis within 6 
hours while plasma was prepared from the remainders by centrifugation and all study 
samples were stored at -80oC until use.       
 
Medical records were retrospectively acquired for all included patients.  Data extracted 
included the characteristics pertaining to the patients (age, sex, fever duration and 
absolute neutrophil counts), underlying haematological malignancy, treatment regime, 
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routine clinical microbiological investigation results (where available) and C-reactive 
protein (CRP) concentrations at time of sampling.   
 
Paper III – Flocked nasal swab  
98 paired samples of nasal and nasaopharyngeal secretions were obtained with the 
flocked nasal swab and NPA apparatus respectively at the same sampling occasion. 
 
 
4.3 METHODS 
 
4.3.1 Flocked nasal swab and nasal pharyngeal aspirate collection  
Paper III 
To minimise carryover from subsequent sampling, nasal secretion samples was first 
obtained with the flocked nasal swab (Copan cp552c) followed by nasal pharyngeal 
aspirate collection with a sterile catheter (Mediplast, no. 8). 
 
Briefly, the fNS was inserted at least 2cm into each of the nostrils and rotated to collect 
as much secretions as possible thereafter, NPA samples were collected by inserting a 
sterile catheter into the posterior nasopharynx and, with gentle suction, secretions were 
collected and flushed with 2-3ml of physiological sodium chloride (Fig. 4.3-1).  Both 
sample types were stored without additional media and transported to the laboratory 
within six hours.  A sample suspension was prepared by shaking the fibre tip of the fNS 
in 500µl RPMI 1640 media, for 30 mins.  Both sample types were stored in -80oC till 
use. 
 
 
 
 
 
 
 
 
 
 
 
Flocked nasal swab Nasal pharyngeal aspirate 
Figure 4.3-1. Schematic diagram of nasal secretion collection with the flocked nasal 
swab (fNS) and nasal pharyngeal aspirates (NPA).  Adapted from (Öhrmalm, 2011) 
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Viral nucleic acids were extracted from 400µl of NPA or fNS suspension sample with 
the BioRobot M48 using the MagAttract virus mini M48 kit (Qiagen GmbH, Germany) 
and eluted in 100µl of nuclease-free water. 
 
 
4.3.2 Quantitative PCR (qPCR) for detection of viruses 
Paper I-II and IV 
Although described extensively only in papers II and III, data from the qPCR runs for 
virus detection was used extensively in papers I and IV as well.  To avoid reinventing 
the wheel, published primers and probes for desired viruses were compiled and checked 
against curated sequences uploaded onto Genbank, NCBI (September 2008) with the 
selection criteria of pan-species coverage whilst retaining specificity.  Where 
unavailable, in-house primers and probes were designed after sequence alignment and 
identification of conserved regions unique to the species.   
 
All completed genomes of the target viruses were obtained from Genbank, NCBI 
(GenBank)  and aligned using ClustalW and conserved regions were eyeballed.  
Additional sequences of the selected conserved region were added to the alignment for 
a construction of a consensus sequence.  Primers and probes targeting the conserved 
region were designed with Primer express (Applied Biosystems) based on the 
consensus sequence.  Table 4.3-1 lists the virus panel utilised as well as the origin of 
the PCR protocol, where it was not designed in-house.     
 
Blood samples were screened for DNA viruses that might reactivate during 
immunosuppression for example, cytomegalovirus (CMV), Epstein-Barr virus (EBV), 
adenovirus (AdV) and other viruses reportedly detected in immunesuppressed patients, 
parvovirus B19 (B19) and BK polyomavirus.  With the NPA samples, respiratory 
viruses circulating in the community were selected for the screening panel.  These 
included human rhinovirus (HRV), human enterovirus (HEV), influenzavirus A and B 
(FluA and FluB), respiratory syncytial virus (RSV), parainfluenzavirus 1-4 (PIV 1-4), 
human coronavirus (HCoV) and human metapneumovirus (HMPV). 
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Table 4.3-1.  Virus screening panel used in this study 
Virus Gene target Dye chemistry Origin 
Blood samples    
Cytomegalovirus 
 
Polymerase Vic-MGB Yun et al. (Yun et al., 2003) 
Epstein-Barr virus BNRF1  Ned-MGB Niesters et al. (Niesters et al., 
2000) 
Adenovirus Hexon 6FAM-MGB Gustafsson et al.  (Gustafson et 
al., 2008) 
BK polyomavirus 
 
VP2,3 Cy5-BHQ3 This study  
Parvovirus B19 NS1 6FAM-MGB This study 
    
Respiratory samples    
Human rhinovirus 
 
5’ UTR 6FAM-BHQ1 Lu et al. (Lu et al., 2008) 
Human enterovirus 5’ UTR Cy5-BHQ3 Nijhuis et al. (Nijhuis et al., 
2002) 
Influenzavirus A 
 
Matrix Vic-TAMRA WHO/CDC 
Influenzavirus B HA 6FAM-MGB Tiveljung-Lindell et al. 
(Tiveljung-Lindell et al., 2009) 
Respiratory syncytial 
virus 
Matrix Cy5-BHQ3 Brittain-Long et al. (Brittain-
Long et al., 2008) 
Parainfluenzavirus 1 HN Ned-MGB Terlizzi et al.  (Terlizzi et al., 
2009) 
Parainfluenzavirus 2 and 3 
 
HN Ned-MGB This study 
Parainfluenzavirus 4 
 
Phosphoprotein Ned-MGB This study 
Human coronavirus Polyprotein 1ab Vic-MGB This study 
Human metapneumovirus 
 
Nucleoprotein Ned-MGB This study 
 
Taqman® real time qPCR assays were used to screen for all the viruses.  Quantitation 
of DNA viruses was achieved with the construction of a plasmid DNA controls 
containing target sequences for respective viruses whereas qualitative analyses were 
performed for the respiratory viruses. 
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4.3.3 Fluorescence-activated cell sorting 
Paper I, II and IV 
In addition to granulocyte counts performed in the clinical laboratories, T-cells, B-cells 
and NK cells were counted as a measure of immune-suppression.  The BD multitest™-
IMK kit with BD Trucount™ tubes (BD Biosciences) were used to measure 
CD3+/CD4+ T helper cells, CD3+/CD8+ T cytotoxic cells, CD3-/CD19+ B cells, CD3-
/CD16+/CD56+ NK cells.  Briefly, 50µL of fresh whole blood is mixed with the BD 
multitest reagents and incubated for 15minutes before lysis and analysis. 
 
 
4.3.4 ELISA  
Paper I and IV 
Commercially available ELISA kits were utilised for measurements of Human plasma 
MBL oligomer (Bioporto, Denmark) and Human plasma sCD14 (R&D systems Inc. 
Minneapolis, USA) concentrations.   
 
 
4.3.5 Single Nucleotide Polymorphism (SNP) identification  
Paper I 
In paper I, SNP genotyping was performed to evaluate the contribution of 
polymorphisms within MBL2 to the frequency or type of infection.  Six SNPs 
previously reported to impact secreted MBL protein concentrations (Madsen et al., 
1995) were selected and a nested PCR approach was undertaken to identify the alleles 
in these loci.  Cytopaenia in this patient cohort limits the amount of DNA available for 
typing hence, a nested PCR approach coupled with capillary sequencing allowed 
efficient use of the restricted starting material. 
 
Multiple sequence alignments against the reference MBL2 were subsequently 
performed to locate each SNP locus and the allele eyeballed and recorded by hand.           
 
 
4.3.6 Chromogenic Limulus Amoebocyte Lysate (cLAL) assay  
Paper IV 
Measurement of bacterial lipopolysaccharides (LPS) was performed with a 
commercially available (Lonza group Ltd., Switzerland)  chromogenic Limulus 
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amoebocytes lysate assay (cLAL) but modified with diazo coupling of the chromogenic 
substrate (Novitsky, 1998) before absorbance measurements.  
 
Using pyrogen-free reagents and consumables (Lonza), heat inactivated plasma were 
aliquoted into a flat-bottom 96 well plate and an initial background absorption 
measurement was taken at this point to correct for variation in the patient’s plasma.  
With the exception of diazo-coupling in the final steps, the assay was subsequently 
performed as recommended by the manufacturer.  All absorption measurements are 
thus taken at 540nm, the maximal absorption for the azo dye.   LPS quantitation in the 
plasma samples were determined against a standard curve of endotoxin standards 
provided in the kit.   
 
 The commercial assay as it was designed was unsatisfactory due to a lack of 
consideration of background absorbance from components within human plasma.  
Further, the absorption wavelength of the chromogenic substrate (p-nitroaniline) was 
not well separated from that of normal human plasma potentiating unreliable 
quantitation of LPS within the sample.  Derivatizing p-aniline (pNA) into its diazo form 
results in a brilliant magenta-coloured dye, measured at 540nm, thus limiting 
interference from plasma components.  Subtraction of background absorption at the 
start of the assay also helps to correct for absorption intrinsic in the plasma itself.   
 
 
4.3.7 Statistical analysis 
Paper I-IV 
With the exception of regression analyses, all statistical analyses were made with the 
Prism suite (Graphpad Inc., CA, USA).  Fisher’s exact test was used for investigating 
categorical data in the patient’s general characteristics.  Non-categorical data were 
analysed either with Mann-Whitney or Kruskal-Wallis test, depending on the number 
of groups.  Correlations were calculated using Spearman’s rank test or Pearson’s 
correlation after log transformation.  In paper I, Wilcoxon signed-rank test was used for 
paired samples and Cohen’s kappa was calculated as a measure of agreement of results 
obtained from the two sampling methods.  All tests were two sided, with p-value < 0.05 
considered statistically significant. 
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In paper II, forward conditional binary logistic regression analyses were performed for 
multivariate analysis of factors associated with fever as the dependent variable.  PASW 
Statistics 18 was used for this purpose. 
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5 RESULTS AND DISCUSSION  
 
The general characteristics of the whole cohort are described in table 5.1-1 and details 
for the patients included in the individual studies are described in the attached 
publications and manuscripts.  Across all studies, no patient presented with clinically 
diagnosed invasive fungal infections. 
 
Table 5.1-1. General characteristics of the entire cohort 
Characteristics 
Fever 
(n=144)  
Without fever 
(n=47)  p-value 
No. of females (%) 61 (42) 19 (40)  n.s. 
Age [years], median (range) 58 (20-86) 62 (28-85)  n.s. 
Underlying disease (%)     
 Acute leukemia/MDS 68 (47) 23 (49)  n.s. 
 Chronic myeloid leukemia 0 (0) 1 (2)  n.s. 
 Chronic lymphocytic leukemia 6 (4) 4 (9)  n.s. 
 Non-Hodgkin lymphoma 45 (31) 14 (30)  n.s. 
 Myeloma 16 (11) 5 (11)  n.s. 
 Hodgkin’s disease 6 (4) 0 (0)  n.s. 
 Others 3 (2) 0 (0)  n.s. 
Cell counta [/mm3], median     
  Neutrophils <100 (<100-500)    200  *** 
  Lymphocytes 107 (2-1002)    437  *** 
  Monocytes 43 (0.02-1337)     78  n.s. 
NOTE. Characteristics are presented in number and percentage of each group. Continuous data are 
presented in medians, followed by range. Continuous data are dichotomized above and below the 
median. OR, odds ratio; CI, confidence interval; MDS, myelodysplastic syndrome. 
a Except for the neutrophil count, data on cell count were only available from 62 of the fever episodes 
and 37 of the controls. 
*** p<0.001 and n.s., not significant 
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5.1 VIRUS DETECTION AND CHARACTERISATION  
(Papers II and III) 
Viral contribution to infection and febrile episodes in this patient group has not been 
well characterised previously and is rather relevant in view of the prolific use of broad-
spectrum antibiotics forestalling potential bacterial infections.  In their 
immunosuppressed condition, bacterial infections account for substantial morbidity and 
mortality (Meckler and Lindemulder, 2009, Bodey et al., 1966, Ellis, 2008) and while 
antibiotic administration is essential  there remains a need for judicious use to limit the 
potential spread of antibiotic-resistant bacterial strains.  Determining the aetiology of 
fevers in this patient group could allow the clinician to make informed decisions on the 
length or discontinuation of broad- spectrum antibiotics.  To this end, we designed the 
study in two parts.  First, we attempted to improve sampling of nasal secretions 
thereafter we assembled a panel of PCR assays targeting blood-borne and respiratory 
viruses. 
 
Nasopharyngeal aspirates (NPA) had been the method of choice when sampling nasal 
secretions but this is wrought with operator-dependent variations and in paediatric 
cohorts, had been a reason for study rejection.  Ease of collection, reduced equipment 
requirement, cost efficacy and ease of transport are some reasons favouring the use of 
the flocked nasal swab (fNS) instead of the nasopharyngeal aspirates.  In paper III, a 
simple study was performed to ascertain the sample collection efficacy with 98 paired 
samples of fNS and NPA.  Quantitative PCR (qPCR) for a panel of respiratory viruses 
and the human beta-actin gene was used to evaluate efficiency for virus sampling and 
general sampling efficacy respectively. 
 
Collection method not-withstanding, in 20 of the 196 samples respiratory viruses were 
detected (table 5.1-2).  Of these, 11 were common to both sampling methods, seven 
only with the NPA and two only with the fNS resulting in a sensitivity of 90% and 65% 
respectively.  With the exception of only one sample, CT values for samples collected 
with NPA was lower than that of fNS suggesting that the NPA method was a better 
method for respiratory virus sampling.  This trend was also reflected in the CT values 
for human beta-actin gene.   
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Table 5.1-2.  Virus detection with the NPA and fNS sampling methods. 
Virus 
No. of samples in which virus was 
detected by: 
Total no. 
Mean difference* in 
Ct values (range) 
Both 
methods 
NPA 
only 
fNS 
only 
Rhinovirus 7 2 0 9 3.2 (-2.0-6.5) 
RSV A 1 1 1 3 5.8 
RSV B 2 0 0 2 2.2 (5.6-9.9) 
Influenza A 0 1 0 1 N/A 
Influenza B 1 1 0 2 15.5 
Bocavirus 0 1 0 1 N/A 
Enterovirus 0 1 0 1 N/A 
Metapneumovirus 0 0 1 1 N/A 
Any virus 11 7 2 20 5.1 (-2.0-15.5) 
*The Ct value for the flocked nasal swab minus the corresponding Ct value for NPA. 
 
The most glaring discrepancy in our study is of course, the depth and location from 
which we collect the NPA and fNS sample; with the NPA, the posterior nasopharynx 
and with the fNS, the outer nostrils.  Attempts to reach the nasopharynx with the fNS 
would result in considerable discomfort to the patient and defeats the primary purpose 
of the study.  Additionally, the suction force used with the NPA collection method 
probably provided better ‘scrubbing’ than simple ‘brushing’ with the fNS.  Admittedly, 
the primary location for viral replication in most cases would not be within the nostrils 
and the initial optimism that respiratory viruses would be carried forward in the mucus 
was probably overestimated knowing that disrupted mucosal response is common in 
this patient group.  Further, most other studies evaluating the efficacy of the flocked 
nasal swabs were performed in otherwise healthy patients that were symptomatic with 
respiratory tract infections.  Even then, no clear association between sampling depth 
and viral detection could be observed (Abu-Diab et al., 2008, Heikkinen et al., 2002, 
Macfarlane et al., 2005, Stensballe et al., 2002, Sung et al., 2008).  Studies that 
compared the use of nasal pharyngeal swabs and nasal pharyngeal aspirates, both of 
which sample the same region, also reported conflicting results (Ahluwalia et al., 1987, 
Cruz et al., 1987, Frayha et al., 1989). 
 
The improved collection efficiency with the NPA, as evidenced by higher yields of 
epithelial cells, indicates the effects of another fundamental difference between the two 
methods.  With the NPA, nasal secretions are collected directly into the collection tube 
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and remnants in the catheter are flushed with saline.  In contrast, nasal secretions 
collected with the fNS need to be transferred upon arrival to the laboratory and we 
cannot exclude the possibility that despite all efforts, not all cells are dislodged from the 
swab into the swab suspension that we use for subsequent analyses.  Overall, we 
concluded that the NPA method for sampling of nasal secretions should not be replaced 
in our adult iatrogenic-immunesuppressed patient group. 
 
With the sampling method in place, we went on further to investigate the prevalence of 
viruses in the iatrogenice febrile neutropaenic adult in paper II.   qPCR assays for a 
panel respiratory and blood-borne viruses were established and viral loads were 
determined with qPCR for CMV, EBV, AdV, parvovirus B19 and BK polyomavirus.  
Qualitative data was obtained with PCR for the respiratory viruses. 
 
In our cohort, we saw that, of the 158 blood samples, 35 (22%) samples were positive 
for at least one blood-borne virus (table 5.1-3) but were all of low viral loads (<1000 
copies/ml) with the exception of 6 samples that included one CMV finding at 1800 
copies/ml, four BKV findings at 3500, 4800, 7000 and 38,000copies/ml and one B19 
finding at 9500copies/ml.  The relevance of these findings however, is debatable as 
these levels are lower than those expected with symptomatic disease. 
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Table 5.1-3. Presence of viruses in peripheral blood and nasopharynx in the 159 
patients with neutropaenia. 
Specimen Virus 
No. of 
positive (%) 
Blood BK polyomavirus (BKV) 18  (11.4) 
n=158 Cytomegalovirus (CMV) 8  (5.1) 
 Parvovirus B19 (B19) 6  (3.8) 
 Epstein-Barr virus (EBV) 6  (3.8) 
 Adenovirus (AdV) 1 (0.6) 
   
No. of patients with at least one virus detected in blood 35  (22.2)a 
   
NPA Rhinovirus (HRV) 11  (7.6) 
n=144 Adenovirus (AdV) 6  (4.2) 
 Respiratory syncytial virus (RSV) 5  (3.5) 
 Influenza A virus (IFA) 1  (0.7) 
 Influenza B virus (IFB) 2  (1.4) 
 Metapneumovirus (HMPV) 2  (1.4) 
   
No. of patients with at least one virus detected in NPA 26  (18.1)b 
   
No. of patients with at least one virus detected in any specimen 56  (35.2) 
a Percentage of total sampling occasions where blood was investigated 
b Percentage of total sampling occasions where NPA was investigated 
 
Correlation of viral loads with disease is problematic, especially with DNA viruses 
capable of latency, as is the case with the CMV and EBV.  This is further confounded 
by reports that EBV DNA has been observed in healthy individuals (Lay et al., 2010).  
Peripheral blood is widely accepted as a sterile environment and any pathogen detected 
should be an indication of an ongoing or ensuing infection which might or might not 
manifest as symptomatic disease.  At the point of detection, the immunocompetent 
individual could already have mounted an effective anti-viral response hence, 
observable disease does not occur.  However, immunosuppression places the patient at 
double-risk; inability to stem the start of an infection and, as a result, inability to 
present with clinical symptoms of the disease.  A contentious suggestion, no doubt, but 
further evaluation is necessary before dismissal.  
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Respiratory viruses were detected in 26 of the 144 NPA samples screened (table 5.1-3) 
and the prevalence of the respective viral species corresponded well with a study on 
community acquired pneumonia in the same geographical area (Johansson et al., 2010).  
Our findings also agree with a previous study suggesting that temporal occurrence of 
viral infections in an immunocompromised patients tend to mirror that of the general 
community (Englund et al., 1999).  It was an unfortunate oversight not to have included 
a control population of matched-healthy adults during the sampling period of the study, 
as a proxy of the circulating respiratory viruses in the particular time and space.  Unlike 
the blood, the respiratory tract is constantly exposed to environmental contaminants and 
association between the detection of viral particles and disease is inherently more 
difficult.  Yet, the likelihood that we would be able to detect transient contaminations is 
presumably rather low too.  Either way, the study would benefit from information depth 
available with quantitation of viral loads and sequencing data to follow time-variable 
changes in viral species/strain findings.     
 
When the patients were stratified based on febrile status (febrile or afebrile), 
significantly more viruses were detected in patients with febrile neutropaenia (42%) 
than afebrile patients (11%).  Although tempting to immediately conclude that virus 
infections are associated with febrile episodes, we have to be mindful that despite 
efforts to match the afebrile patients, they remain less immunosuppressed as indicated 
by their leukocyte cell counts.  With fever as the dependent variable, multivariate 
regression analysis to include cell counts and other confounding factors (with p-value < 
0.10) listed in table 2 was performed and, the association between fever and presence of 
virus remained.  Moving ahead with caution, we conclude that febrile episodes with 
viral findings should be considered as infections till otherwise indicated. 
 
The association between bacterial findings and febrile episodes is well established and 
33% of the febrile neutropaenic episodes in our study are attributed to bacteraemia.  In 
our study, we add to the field with our observation suggesting that, a further 30% of 
these febrile episodes are associated with viral findings (Fig. 5.1-1).  The aetiology of 
fever in the last third of the group remains unknown and are thus categorised as patients 
with fever of unknown origin (FUO).  This study would have benefitted with follow-up 
study samples to verify the association between viral findings and fever and, should 
definitely be considered in the future. 
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None
37%
Virus
30%
Virus and 
bacteria
12%
Bacteria 
21%
Bacteraemia 33% 
Figure 5.1-1. Documented microbiological findings in 123 febrile neutropaenic patients. 
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5.2 MICROBIAL TRANSLOCATION CONTRIBUTES TO EPISODES WITH 
FEVER OF UNKNOWN ORIGIN  
(Paper IV) 
Despite extensive microbiological investigations, approximately 30% of febrile 
episodes in our cohort have no known cause, termed fever of unknown origin (FUO).  
Sterile fevers have of course been associated with the haematological malignancy itself 
or, as a result of the cytotoxic treatment these patients undergo.    However, intestinal 
mucosal damage and the subsequent inflammation-mucositis is a common occurrence 
in our patient group as a result of cytotoxic agents administered for treatment of their 
underlying disease. Further, microbial translocation has been reported in studies with 
immunocompromised HIV-1 infected cohorts (Redd et al., 2009, Brenchley et al., 
2006).  This study then sets out to determine if fever in patients categorised as FUO, 
could be attributed to microbial translocation from the gastrointestinal tract.   
 
Endotoxins more specifically, lipopolysaccharides (LPS), are commonly found on the 
outer membrane of Gram-negative bacteria and is used in this study as a measure of 
microbial translocation.  Additionally, sCD14 was also measured concurrently to 
ascertain host response to LPS in this immunosuppressed patient cohort. 
 
In our study, we observed elevated endotoxin concentrations, in concurrence with HIV-
1 infected immunosuppressed cohorts (Brenchley et al., 2006) but not between the 
febrile and afebrile episodes.  Further stratification of the febrile episodes based on 
microbiological findings revealed that despite the elevation across the cohort, episodes 
with documented bacteraemia (median=104.7 pg/ml [87.1pg/ml-112.3pg/ml]) had 
higher endotoxin concentrations compared with those of viral findings (median=97.3 
pg/ml [85.45pg/ml-109.4pg/ml]).  Endotoxin concentrations from FUO episodes 
(median=111.8 pg/ml [99.8pg/ml-134.9pg/ml]) were even higher than bacteraemia 
episodes, suggesting that there is similar, if not more, circulating bacterial products in 
this group.    
 
Since fever is a manifestation of host response to LPS, the corresponding host sCD14 
concentrations could explain the similarities in endotoxin concentrations between the 
febrile and afebrile episodes.  As expected, sCD14 concentrations were significantly 
higher in the febrile episodes compared to the afebrile episodes suggesting that a host 
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response mediated through sCD14 binding of LPS has been initiated, leading to the 
development of fever as a symptom and implicating afebrile patients potentially as 
inadequate responders (Fig. 5.2-1).  Stratification of the febrile episodes to focus on 
episodes with bacterial findings  and the FUO episodes revealed similar sCD14 
concentrations in both the FUO (3.20 x106 pg/ml [2.29 x106 pg/ml- 3.80 x106 pg/ml]) 
and Gram-negative bacteraemia (3.34 x106 pg/ml [2.52 x106 pg/ml- 4.01 x106 pg/ml]) 
episodes and that they were higher than those observed in episodes with Gram-positive 
bacteraemia (2.55 x106 pg/ml [1.87 x106 pg/ml- 3.07 x106 pg/ml]).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
It is intriguing that the sCD14 concentrations do not mirror that of the endotoxin 
concentrations and could be attributed largely to the inherent immunosuppressed state 
of this patient group.  Antineoplastic treatment these patients are subject to drastically 
reduces the monocytes and neutrophil populations and since these cells have been 
suggested to be the main sources of sCD14, a stunted response could be likely.  The 
dual role of sCD14 further confounds explanation of the findings.  In low 
concentrations, sCD14 transfers LPS to mCD14 and TLR4 to initiate a pro-
inflammatory response however at high systemic concentrations, sCD14 acts as an 
attenuator to cell responses by shuttling LPS to lipoproteins (Kitchens and Thompson, 
2005).  sCD14 alternates between these two roles in a bid to launch a pro-inflammatory 
response in the presence of invading pathogens whilst attempting to limit bystander 
Fig 5.2-1 sCD14 concentrations in relation to febrile status.  Dotted line 
indicates sCD14 concentrations in healthy individuals as reported in 
(Brenchley et al., 2006) 
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tissue damage at the same time.  To tease apart the role sCD14 is playing in our patients 
would require analyses of downstream proteins however, the transient and equilibrium-
seeking nature of sCD14 might render this a rather difficult task.   
 
Nonetheless, the elevated endotoxin and sCD14 concentrations observed in our patient 
group suggest that microbial translocation from the gastrointestinal tract has indeed 
occurred and could also contribute to the presentation of fever in the FUO episodes.  
The similarity of our findings to that of other immunosuppressed cohorts where 
microbial translocation has been established reinforces our conclusion. 
 
Another interesting finding in this study was that the use of prophylactic antibiotics was 
associated with higher plasma endotoxin concentrations (Fig. 5.2-2).  Liberal use of 
prophylactic antibiotics is commonplace in iatrogenic patients as a pre-emptive 
measure to bacterial infections yet our findings suggest that oral prophylactic 
antibiotics might predispose patients to increased risk of microbial translocation leading 
to fevers and subsequent delays in chemotherapy cycles.  Without additional 
parameters such as type, dose and duration of prophylactic antibiotic use, it would be 
imprudent to speculate further.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5.2-2 Endotoxin concentrations with (n=48) and without (n=55) 
prophylactic antibiotic use.(   ) bacteria episodes; (  ) FUO episodes; (  ) 
virus episodes 
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Earlier studies had presented conflicting results, reasons for which lie mostly with 
variations in methodology, sample sizes and inclusion criteria (table 5.2-1) and 
interpretation of our findings in context with earlier studies are inherently difficult. 
 
Table 5.2-1. Studies on markers of microbial translocation in the chemotherapy-induced 
immunosuppressed patient. 
Ref. Numbers  
(Sampling regime) 
Measures of microbial 
translocation 
Microbial translocation? 
(Harris et al., 
1984) 
100  
(With and without 
chemotherapy) 
Endotoxin with cLAL 
assay1 with OD at 405nm 
as quantitation. 
No 
 
(Tancrede and 
Andremont, 
1985) 
680 
(Faecal samples 
twice a week after 
chemotherapy and 
peripheral blood 
samples at onset of 
neutropaenia)  
Concurrent positive 
bacterial cultures from 
blood and faeces. 
Yes, observed in 55/64 
documented Gram-negative 
bacteraemia episodes. 
 
(McCartney et 
al., 1987) 
10  
(Daily, post 
chemotherapy) 
Endotoxin with cLAL 
assay1 
Unclear. Endotoxaemia was 
associated with Gram-negative 
bacteraemia but the reverse is 
not always true. 
 
(Gunther et al., 
1995) 
94 
(Fever onset, , day 
1,2 and 6 thereafter) 
Endotoxin with cLAL 
assay1 
Unclear. Mean endotoxin 
concentration were similar with 
and without bacteraemia. 
Wong, M 
(current) 
93   
(within 3days of 
febrile neutropaenia 
onset) 
Endotoxin with cLAL 
assay1and sCD14. 
Yes.   Both endotoxin and 
sCD14 concentrations were 
higher in FUO episodes than in 
Gram-negative bacteraemia 
episodes. 
1 Chromogenic Limulus amoebocyte lysate assay. 
2 Optical density units 
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5.3 MBL2 POLYMORPHISMS AND INFECTION SUSCEPTIBILITY  
(Paper I) 
Infection episodes are common in this patient group during the neutropaenic phase and 
account for significant mortality (Pizzo, 1999).  This is largely due to the 
immunosuppression from antineoplastic treatment the patients undergo for their 
underlying haematological disease.  Promising results from previous studies had 
suggested that patients deficient in secreted mannose-binding lectin (MBL) could be 
more susceptible to infections (Molle et al., 2006, Mullighan et al., 2002, Neth et al., 
2001, Peterslund et al., 2001).  In fact, the use of recombinant MBL has been put 
through phase I clinical trials in Denmark (Petersen KA).  The results from our study 
however show that in a Swedish adult iatrogenic patient cohort, neither MBL2 SNPs 
nor plasma MBL levels did not correlate to infection risk or type.   
 
In 96 febrile neutropaenic episodes and 33 afebrile neutropaenic episodes, plasma MBL 
concentrations were measured and MBL2 SNP genotypes were determined.  We first 
established that the allele frequency of the six MBL2 SNPs and the corresponding 
haplotypes in our patient group were in Hardy-Weinberg equilibrium with a reference 
Danish population (Madsen et al., 1995) (table 5.3-1).   
 
Table 5.3-1.  MBL2 genotype frequencies observed in this cohort (n=108). 
Promoter    Exon 1    Total  
dbSNP ID allele n (%)  dbSNP ID allele n  (%)  Genotype n (%) 
rs11003125 L/L 47 (43.5)  rs5030737 A/A 96 (88.9)  A/A 63 (58.3) 
 L/H 46 (42.6)   A/D 12 (11.1)  A/O 39 (36.1) 
 H/H 15 (13.9)   D/D 0 (0.0)  O/O 6 (5.6) 
          
rs7096206 Y/Y 67 (62.0)  rs1800450 A/A 75 (69.4)    
 Y/X 34 (31.5)   A/B 30 (27.8)    
 X/X 7 (6.5)   BB 3 (2.8)    
          
rs7095891  P/P 69 (63.9)  rs1800451 A/A 104 (96.3)    
 P/Q 31 (28.7)   A/C 4 (3.7)    
 Q/Q 8 (7.4)   C/C 0 (0.0)    
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We further ascertained the correlation of the MBL2 SNPs to plasma MBL 
concentrations and could be used to predict MBL deficiencies (p< 0.001).  Briefly, 
plasma MBL concentrations were drastically reduced in the presence of SNPs within 
the exon 1 coding region and the X/Y SNP in the promoter region playing only a 
secondary role (Fig 5.3-1).   With this in mind, subsequent statistical analyses with 
clinical parameters were performed only with the coding region genotypes (A/A, A/O, 
O/O) to be statistically meaningful. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The two main clinical endpoints determined for this study were infection type and 
frequency, with presentation of fever as an indicator for infection.  An episode-centric 
approach was taken for analyses with infection type among the febrile episodes without 
SNPs in the coding region (A/A).  No difference in plasma MBL concentrations was 
observed between episodes with bacterial findings, bacterial or viral co-findings, and 
viral findings.  In fact, plasma MBL concentrations were similar regardless of 
microbiological findings.  This finding mirrors that of CRP concentrations, another 
acute phase protein, and could indicate disruptions in the acute phase response, 
presumably as a consequence of the antineoplastic treatment these patients have 
undergone.  Interestingly, while MBL concentrations did not vary with the presentation 
of fever, CRP concentrations did, leading to postulations on the varied functions 
between these two proteins. 
Fig 5.3-1 MBL2 genotypes with the corresponding plasma MBL 
concentrations (***p<0.001) 
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Using fever as an indicator of infection, we further performed patient-centric analyses 
to determine associations between MBL2 coding region genotypes (A/A, A/O and O/O) 
and risk of fever and fever duration.  No correlation was observed with MBL2 
genotypes and the risk of fever but a significant reduction in fever days per 
neutropaenic episode was observed in patients with the A/O and O/O genotype.  The 
median number of febrile days per neutropaenic episode for A/A individuals was 3 
days (IQR=2.0-4.7) compared to 1.8 days (IQR=1.0-3.8) for A/O and O/O individuals.  
Antibiotic use, which corresponds closely to fever duration, revealed the same trend 
with A/A and A/O+O/O individuals (Fig. 5.3- 2).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This finding adds to the body of studies with conflicting results regarding the relevance 
of MBL (Bergmann et al., 2003, Kilpatrick et al., 2003, Peterslund et al., 2001, 
Vekemans et al., 2007, Martinez-Lopez et al., 2009, Klostergaard et al., 2010, 
Mullighan et al., 2002) among immunosuppressed adults with underlying 
haematological disorders (Table 5.3-2).   
Fig 5.3-2 The proportional days of fever during febrile neutropaenia 
episodes among A/A (n=46) and A/O+O/O (n=41) 
individuals.*p<0.05) 
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Table 5.3-2.  Studies on the relevance of MBL2 and MBL protein concentrations in the chemotherapy-induced immunosuppressed adult patient. 
Ref Country, 
time period 
Underlying 
disease 
(neutropaenia) 
Numbers  
(Sampling regime) 
Association to MBL measures 
Fever Infection 
(Peterslund et 
al., 2001) 
Denmark, 
N.A. 
 Mixed 
haematological 
malignancies  
(N.A. ) 
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(Before chemotherapy) 
N.A. 
 
 
Yes  MBL protein 
(Kilpatrick et 
al., 2003) 
Glasgow 
UK,   
N.A. 
Mixed 
haematological 
malignancies 
(1000cells/mL) 
134 mixed  bone marrow 
conditioning and 
chemotherapy.  
(Before treatment, 
neutropaenia onset, after 
neutrophil recovery) 
 
No. 
  
Yes. MBL<=0.1ug/ml 
had highest frequency 
of major infections.  
 
MBL protein 
(Bergmann et 
al., 2003) 
Denmark, 
1990-1993 
Acute myeloid 
leukaemia 
(N.A.) 
 
 
80   
(Day of antineoplastic therapy 
iniatiation and weekly 
thereafter till day 28 ) 
No. 
 
No. MBL protein 
(Molle et al., 
2006) 
Denmark, 
1994-2003 
Multiple myeloma 
(N.A.) 
138 VAD1 or Cydex2 treated 
(N.A.) 
 
N.A. No MBL2 genotype 
(Klostergaard 
et al., 2010) 
Denmark, 
1993-2004 
Acute myeloid 
leukaemia 
(N.A.) 
190  
(Bone marrow  aspirates) 
N.A. No.   MBL2 genotype 
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(Mullighan et 
al., 2002) 
 
 
 
Australia, 
2002-2006 
 
 
Mixed 
malignancies 
(Not available)  
 
 
 
142 sibling HLA matched allo- 
HSCT (Pretransplantation 
conditioning, day 0,14,28 post 
transplantation) 
 
 
 
 No.   
 
 
Yes.  A/O and O/O 
are weak risk factors 
for infections  
 
 
 
MBL2 coding 
region genotype 
and MBL protein 
(Vekemans et 
al., 2007) 
Not 
available, 
2001-2003 
Mixed 
haematological 
malignancies 
(<500cells/mL) 
 
255   
(Day 1 of chemotherapy or 3 
days before chemotherapy) 
No. 
 
Yes.. MBL2 genotype 
and MBL protein 
(Wong et al., 
2012) 
Sweden, 
2008-2010 
Mixed 
haematological 
malignancies 
(<500cells/mL) 
 
82   
(within 3days of febrile 
neutropaenia onset) 
No but among febrile 
episodes, ratio of 
fever per neutropaenic 
day was higher in A/A 
than A/O+O/O 
patients. 
No. MBL2 genotype 
and MBL protein 
1 Vincristine, doxorubicine, dexamethasone 
2 Cyclophosphamide and dexamethasone 
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Indeed, promising results from previous studies had been in paediatric oncology 
cohorts (Neth et al., 2001) but a recent meta-analysis of these studies has revealed that 
MBL deficiency could not be identified as risk factor for infection in these patients 
(Frakking et al., 2011).  A similar meta-analysis for adults should be performed 
although our findings make it apparent that the relevance of MBL is limited and further 
clinical trials are unnecessary. 
 
What’s more fascinating is the general elevation of MBL concentrations in this patient 
group.  Unfortunately, a healthy control group was not included in this study but simple 
comparisons with previous studies reporting MBL concentrations in blood bank donors 
suggest that MBL concentrations are elevated in our study.  This finding was presented 
in some earlier studies (Bergmann et al., 2003, Kilpatrick et al., 2003) but was 
regrettably not further discussed. In vitro studies conducted with human colon 
adenocarcinoma cell lines demonstrated that MBL does indeed bind directly to 
transformed cell lines exhibiting aberrant  glycosylation patterns (Muto et al., 1999).  
Conceivably, the preceding chemotherapy treatment the patients underwent could have 
already stimulated an increase in MBL concentrations as a means to facilitate removal 
of dead cells via phagocytosis.  Thus, the MBL response to ensuing infection could 
have been masked.  Put together, further studies regarding the function of MBL would 
be interesting but studies leading to therapeutic benefit of human recombinant MBL in 
this patient group is doubtful. 
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6 CONCLUSION AND FUTURE PERSPECTIVES 
 
With these iatrogenic neutropaenic patients, we have attempted to further dissect the 
aetiology of the fever.  In the neutropaenic patient, fever is the foremost and sometimes, 
only indication of infection with other signs of inflammation minimal or even absent. 
Treatment for their underlying hematological malignancy with cytotoxic drugs renders 
these patients highly susceptible to pathogenic infections which, would have been 
easily cleared in a healthy individual.  The use of prophylactic broad-spectrum 
antibiotics has been imperial in preventing fatal bacterial infections but we would like 
to put forward a future case for better informed use of antibiotics after acute-empirical 
assessment via discrimination between infectious and non-infectious fevers and, 
bacterial and non-bacterial infections. 
 
Bacteraemia in this patient group is well established (Klastersky et al., 2007, Whimbey 
et al., 1987, Viscoli et al., 2005)  and we had no intention of disputing the fact however, 
we propose that viral contribution to infections or fever should be better studied.  Aside 
from reports of reactivation of latent DNA viruses for example, CMV (Holmberg et al., 
1999, Metselaar and Weimar, 1989, Rajcani, 2007), and EBV (Babcock et al., 1999, 
Baldanti et al., 2000, Crawford et al., 1981, Yao et al., 1985), the panorama of viral 
infections in the immunosuppressed patient that have not undergone HSCT, is not well 
studied.  During immunosupression, patients are not often confined to the hospital and 
are thus potentially exposed to viruses to the same extent as the general community.  
Our work in paper II describes the prevalence of nine common respiratory 
viruses and show that it is congruent with the general prevalence in this 
geographical population.  Additionally, an association between virus detection and 
fever was observed suggesting viral contribution to 30% of neutropaenic febrile 
episodes.  Although significant, we cannot ascertain that the association was causative. 
qPCR is a highly sensitive method for viral detection but its strength is sometimes its 
bane.  Ability to detect minute quantities of viral nucleic acid does not necessarily mean 
a viral infection has occurred.  In fact, determining the viral copy numbers and its 
relation to viral infections is rather tricky.  With blood samples, one assumes a sterile 
environment hence the presence of any viral nucleic acid warrants concern yet, it is 
suggested that a clinical threshold is necessary to constitute and infection (Bai et al., 
1997, Baldanti et al., 2000, Jebbink et al., 2003, Kimura et al., 1999, Lay et al., 2010, 
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Limaye et al., 2001, Mullier et al., 2009, Rowe et al., 1997, Wagner et al., 2004) .  In 
the respiratory tract, where one is constantly exposed to environmental factors, it is 
perhaps even less surprising that viral nucleic acids are detected.  To further confound 
the issue, infection with some respiratory viruses like HRV is not always associated to 
symptomatic fever (Jansen et al., 2011, Wright et al., 2007). The key question really is 
how we can correlate viral nucleic acid detection to viral infection.  Longitudinal 
studies with samples taken regularly could be a means where viral load can be tracked 
in relation to the patient’s symptoms.  Detection of viral replication intermediates could 
be another option to demonstrate active replication within the host (Bannister et al., 
2010, de Paula et al., 2009, Vaughan et al., 2008, Zawilinska et al., 2006, Zawilinska et 
al., 2008).  Regardless of the study design, the fact remains that in most individuals, 
there is a threshold of viral copy numbers only beyond which, viral infection takes 
place with the corresponding symptoms.  Nonetheless, for the purposes of this thesis, 
viral findings are assumed to be viral infections and this categorisation is used in papers 
I and IV. 
 
Despite 33% of the febrile episodes attributed to bacteraemia and a further 30% to viral 
findings, 37% of febrile episodes still have no attributable cause (Fig. 5.1-1).  Drug and 
treatment related fever (DTRF) is of course a possibility and often suggested where 
fever of unknown origin (FUO) is documented.  The observed microbial translocation 
in another immunosuppressed group of HIV-1 infected patients suggests that a similar 
situation could occur in our patients.  In paper IV, we show that microbial 
translocation does indeed occur in our cohort and that fever in FUO episodes can 
be attributed to microbial translocation.   The association of sCD14, but not 
endotoxins, to fever suggests that some level of immune response is required in order to 
launch a cascade, leading to fever as an observable symptom.  Antineoplastic treatment 
these patients undergo, primarily affects the cellular components of the immune system 
rendering acellular components of the innate immune system, such as MBL, potentially 
important in the role of microbial defence.  The ability to predict infection 
susceptibility from MBL genotype is appealing but in our hands (paper III), we saw 
no association between MBL2 genotypes to frequency or type of infection. 
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Put together, we, 
 
a. Suggest that 30% of febrile neutropaenia could be associated to viral findings; 
 
b. Show that microbial translocation contribute to fever in FUO episodes; 
 
c. Show no association between MBL2 genotypes and infection suggesting 
recombinant therapy is not relevant in this patient group. 
 
 
The critiques to this study are naturally, many.  Working with humans, limit the amount 
of experimental manipulations and highlights the need for good study design.  
Although all patients comply with the criteria of immunosuppression, the heterogeneity 
of their underlying haematological disease is not ideal.  By virtue of their differing 
disease, treatment varies and potentially alteration of their immune system as well.  
Much is also to be desired regarding the selection of appropriate controls and 
stringency in matching them, especially with regard to immunosuppression.  As a 
cross-sectional study, it has fulfilled its purpose of offering a snapshot and allowing 
exploration of possible correlates to fever.  Moving forward, a longitudinal study with 
samples taken before chemotherapy and at various timepoints thereafter should be 
performed to address fever causation.   
 
Nonetheless, at this juncture, we put forward the notion that when faced with a febrile 
neutropaenic patient, in addition to the usual suspects of malignancy, drug and 
infectious complications of bacteraemia and fungaemia, viral infections and microbial 
translocation should be added to the lineup.  The need for diagnostic tools and 
biomarkers that can effectively distinguish between these causes is thus vital for the 
administration of appropriate treatment modalities.  
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7 POPULAR SCIENCE SUMMARY 
 
There has been drastic improvement in the way we treat blood cancers but the very 
treatment we use is toxic both to the malignant cancer cells as well as to the cells in our 
immune system.  Nonetheless, this is a necessary evil and the only recourse is to treat 
the ensuing infections as they occur, with antibiotics and supportive care. 
 
Most of the infections faced by patients immunosuppressed from the cytotoxic 
chemotherapy are from bacteria we encounter daily.  Normally, harmless, infections in 
the immunosuppressed patient can potentially be fatal hence, antibiotics are usually 
prescribed upon manifestation of fever or, even in anticipation of infection.  This has 
led to much concern regarding the spread of antibiotic-resistant bacteria and the fear 
that we may soon run out of ‘new’ antibiotics capable of killing these antibiotic-
resistant strains of bacteria looms near.   
 
In an effort to limit the unnecessary use of antibiotics, we have set out to determine the 
prevalence of viral infections in this patient group.  Should we be able to accurately 
diagnose and differentiate between the various infection types, we should hopefully 
then be able to administer the relevant drugs for bacterial, viral or fungal infections.  In 
our study with immunosuppressed patients, we have found viruses in 30% of the fever 
episodes where neither bacteria nor fungi are detected.  We thus conclude that these 
fever episodes might be attributed to viral infections.  This 30% with virus findings 
together with another 33% with bacteria findings still leave us with a remaining 37% of 
fever episodes where no pathogen could be detected. 
 
Another side effect of the cytotoxic chemotherapy these patients encounter is the 
disruption of the lining in their gastrointestinal tract.  This lining accounts for a large 
part of our immune system and works daily to prevent the bacteria we harbour in our 
lower intestines from entering our bloodstream.  Disruption of this layer would 
naturally put us at risk and indeed, we see that in the patients that have fever but no 
pathogen detected, higher levels of bacterial products are observed in their blood.  
Together with the virus findings, we suggest possible causes for the fever episodes 
experienced by these patients. 
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Lastly, we also investigated the specific role of a protein in the immune system, 
mannose-binding lectin (MBL) against infection and fever in our patients.  The 
availability commercially makes this protein an attractive choice as we could 
potentially administer it to the patients, helping them defend against infections while 
reducing antibiotics use.  Unfortunately, in our study, we did not see any protective 
MBL effect in our patients.  
 
In conclusion, we have added to the panorama of infectious agents and bacterial 
products implicated during fever episodes in the chemotherapy-induced 
immunosuppressed adult patient and have further discouraged suggestions for MBL 
replacement therapy. 
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